Review Article

Majid Ghareghani, Amir Ghanbari, Ali Eid, Abdullah Shaito, Wael Mohamed, Stefania Mondello, Kazem Zibara*

Hormones in experimental autoimmune encephalomyelitis (EAE) animal models

https://doi.org/10.1515/tnsci-2020-0169
received January 17, 2021; accepted April 14, 2021

Abstract: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) in which activated immune cells attack the CNS and cause inflammation and demyelination. While the etiology of MS is still largely unknown, the interaction between hormones and the immune system plays a role in disease progression, but the mechanisms by which this occurs are incompletely understood. Several in vitro and in vivo experimental, but also clinical studies, have addressed the possible role of the endocrine system in susceptibility and severity of autoimmune diseases. Although there are several demyelinating models, experimental autoimmune encephalomyelitis (EAE) is the oldest and most commonly used model for MS in laboratory animals which enables researchers to translate their findings from EAE into human. Evidences imply that there is great heterogeneity in the susceptibility to the induction, the method of induction, and the response to various immunological or pharmacological interventions, which led to conflicting results on the role of specific hormones in the EAE model. In this review, we address the role of endocrine system in EAE model to provide a comprehensive view and a better understanding of the interactions between the endocrine and the immune systems in various models of EAE, to open up a ground for further detailed studies in this field by considering and comparing the results and models used in previous studies.

Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, EAE, endocrine system, hormone

1 Introduction

The endocrine system (ES) consists of numerous glands which regulate many physiological processes by producing hormones throughout the body [1]. The interconnections between the ES and the central nervous system (CNS) are significant since both are involved in maintaining homeostasis whereby fluctuations in the ES could cause pathological situations in the CNS [2]. Over the past 40 years, it has been reported that activation of the immune system is associated with alterations in the neuroendocrine functions, indicating that its functions are under the supervision of the CNS [3]. ES hormones can bind to the receptors on a wide range of cell types ranging from immune cells to neural cells which would affect the function of these cells.

The therapeutic activity of hormones has been investigated in multiple sclerosis (MS), an inflammatory demyelinating disease of the CNS in which activated immune cells attack the CNS. Although the symptoms are different from patient to patient, all patients have demyelination in common. Demyelination interferes with normal signal conduction along neuronal axons, ultimately resulting in a number of clinical symptoms affecting the autoreactive immune responses and myelination [4]. Depending on
the manner by which the disease attacks the body over time, reversible/irreversible sequelae would develop. (A) Relapsing-remitting MS (RRMS) is the most common kind of MS in which the severity of the disease is followed by partial or complete recovery, known as remission. This remission is itself followed by relapses and exacerbations of symptoms, a cycle that is repeated over time. (B) Secondary-Progressive MS (SPMS); patients do not show the relapse/remission cycle; instead, the disease severity progresses steadily. (C) Primary-Progressive MS (PPMS) comprises a small group of MS patients in which a steady accumulation of disabilities occurs without attacks. (D) Progressive-Relapsing MS (PRMS) is another rare kind in which the disease severity worsens steadily, with acute relapses but without remissions [5]. Although the etiology of MS is still not known, a wide range of factors have been implicated in the pathogenesis of the disease including genetic risk factors, environmental risk factors such as Epstein-Barr Virus, sunlight, vitamin D, and smoking, and lifestyle risk factors such as diet and microbiota. This has been nicely reviewed by Nourbakhsh and Mowry [6].

Animal models such as Experimental Autoimmune Encephalomyelitis (EAE) have been extensively used to investigate the potential therapeutics for MS [7]. While the sensitization to autoantigens naturally happens due to an unknown mechanism, the EAE model needs an external immunization [8]. EAE is an organ-specific cell-mediated autoimmune demyelinating disease of the CNS in which macrophages and T lymphocytes mediate the injury to myelin sheath. Considering the multifactorial nature of MS etiology and the complexity of the inflammatory and immunological processes, several protocols have been used for EAE induction in mice and rats [9,10]. There are some recognized antigens in MS, which act as a target of B and T cell response, such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), myelin-associated glycoprotein (MAG), and proteolipid protein (PLP) [11]. These peptide antigens are emulsified in Complete Freund’s Adjuvant (CFA), an enhancer of autoantigens’ immunogenicity in EAE induction, and then subsequently injected to induce demyelination and neuroinflammation in mice. In addition, this model needs another agent, Pertussis toxin (PT), to open up the blood-brain barrier and facilitates the migration of pathogenic T-cells into the CNS [12].

This review covers endogenous hormonal alterations involved in immune cell functions and demyelination in EAE. Pharmacologically, this review includes exogenous hormonal administration that can influence EAE. This review brings many hypotheses and ideas to the attention of the reader to fill the current gaps in the existing studies to ultimately reach a thorough understanding of the role of all hormones in EAE onset and development. It is worth noting that some hormones have conflicting effects in the EAE model. It is not clear whether this is due to age, gender, immunogen, or strain of the EAE animal model. We categorized in separate tables all the studies mentioned in this review according to the above-mentioned factors, indicating at the end of each endocrine system the hormones that have been studied in the EAE animal models.

2 The pituitary gland

2.1 Anterior lobe of pituitary

2.1.1 Luteinizing hormone (LH)

Increased serum level of LH has been demonstrated in male, but not female, passive EAE mice, compared to control mice [13]. This suggested that gonadal dysfunction occurs in males during passive EAE, but not females. Importantly, ovariectomized mice showed significantly higher level of LH in this group.

2.1.2 Prolactin (PRL)

Riskind et al. investigated prolactin in response to EAE induction and bromocriptine, a dopamine agonist. Elevated levels of prolactin were found after immunization with EAE induction emulsion and before EAE onset [14]. Importantly, bromocriptine not only suppressed the severity of EAE, but also inhibited the secretion of prolactin both in serum and pituitary. This suggested that prolactin is involved in immune response during EAE. Moreover, plasma prolactin was markedly suppressed by bromocriptine treatment initiated after the onset of EAE symptoms [15]. To support this idea, Canonico et al. treated Lewis rats, 2 days ahead of EAE induction, with dihydroergocryptine, a natural alkaloid derivative which exhibits D2 dopaminomimetic properties [16]. They demonstrated that dihydroergocryptine medication markedly reduced the prolactin level, compared to untreated-EAE rats, which also led to amelioration of EAE severity.

Since dopaminergic agonists therapy in EAE reduces the severity of disease and prolactin level, Esquivino et al. investigated whether ectopic pituitary would affect EAE...
and prolactin [17]. Therefore, pituitary grafting from littermate donors was performed and then rats were immunized by EAE induction emulsion. Only sham-operated rats exhibited EAE symptoms, whereas prolactin plasma level started to increase from the first day postimmunization. In contrast, prolactin decreased in pituitary-grafted rats and reached its lowest level on day 15 after immunization, without showing any signs of EAE symptoms. In another group of experiments, bromocriptine-treated rats did not show any sign of EAE and also had very low concentration of prolactin in the plasma, whereas prolactin was constantly high in untreated-EAE rats, which showed first sign of EAE symptoms on day 15. In summary, low level of circulating prolactin coincided with absence of clinical symptoms of EAE. However, Costanza et al. challenged this common view and reported, using PRL-deficient (Prt−/−) and PRL receptor-deficient (Prlr−/−) mice, that prolactin is not required for the development of EAE [18]. Indeed, PRL or PRLR couldn’t impair the development of Th1 and Th17 responses against MOG35-55, but only delayed their generation before a full clinical severity was observed, similar to wild-type EAE mice. Interestingly, it has been recently claimed that prolactin synergistically enhances the efficiency of interferon-β in amelioration of EAE severity, while prolactin alone did not affect EAE development. These findings introduced prolactin as a beneficial factor to increase the therapeutic potential of interferon-β in MS [19]. In contrast, another study suggested that inhibition of elevated prolactin by antigen-presenting cells ameliorates the EAE severity. Taking into account that induction of pathogenic eomesodermin-positive CD4+ T cells is associated with a transition from an acute stage to a later stage in EAE, Zhang et al. showed that the expression of prolactin is enhanced in late EAE lesions by B cells and MHC class II+ myeloid cells [20].

2.1.3 Growth hormone (GH)

EAE can be significantly modified by caloric restriction since calorie restricted EAE rats showed significantly reduced levels of GH, compared to controls [21]. To distinguish the role of GH and GH-releasing hormone (GHRH) in EAE development, Shohreh et al. used a GHRH knockout mouse (GHRH−/−) to induce EAE [22]. Results showed that untreated and GHRH super agonist JI-38-treated GHRH−/− mice had lower susceptibility to EAE, compared to control and GH-treated GHRH−/− mice. Importantly, GH-treated GHRH−/− mice showed severe clinical scores, compared to controls, associated with a considerable increase in spleen size and T-cell proliferation specific to MOG peptide. Therefore, GH plays a key role in the development of EAE, but not GHRH.

2.1.4 Adrenocorticotropic hormone (ACTH)

The neurotrophic peptide [H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH], a synthetic analog of ACTH [4–9], was used by Duckers et al., to study its effect in EAE model. They found that repeated subcutaneous injections of this analog suppressed the development of EAE-related clinical symptoms, improved motor performance, and reduced the reaction time upon thermal stimulation, in comparison to untreated-EAE mice [23]. This analog also protected against the development of EAE symptoms by improving the visual evoked potentials of animals suffering from EAE [24].

Weidenfeld et al. examined the effect of linomide (quinoline-3-carboxamide), a novel synthetic compound with various immunomodulatory properties, on adrenalectomized EAE rats. Linomide-treated EAE-adrenalectomized rats did not develop any signs of EAE, in comparison to untreated EAE-adrenalectomized rats which showed high EAE clinical scores. Moreover, a marked reduction in thymus weight was seen in the linomide-treated, compared to untreated, EAE-adrenalectomized rats [25].

The hormonal change in EAE was also investigated in Lewis (LEW), Brown Norway (BN), and Dark Agouti (DA) rat strains. Basal ACTH levels were found in BN and DA rats, whereas lower levels were observed in LEW rats. These strains showed different susceptibilities to EAE induction [26]. On the other hand, although some studies reported a slight insignificant increase in ACTH plasma level in EAE Lewis rat, compared to control [27–30], Ruocco et al. showed a sharp and significant increase in ACTH in the same animal model [31].

Treatment with Acthar gel, an FDA-approved medication for acute MS and a highly purified gel preparation of porcine ACTH1-39 [32], was used in female EAE mice. This gel ameliorated the severity of EAE clinical scores and protected EAE by reducing immune cell infiltration and demyelination of spinal cord. In addition, activated microglia and macrophages were measured via Ricinus communis agglutinin (RCA)-1 lectin histochemistry and found fewer RCA-1+ cells in the spinal cords of Acthar-treated mice compared to untreated-EAE mice at, or after, the onset of relapse. Moreover, Acthar gel treatment markedly suppressed ex vivo myelin peptide-induced CD4+ T cell proliferation [33], as activation of T cells reactive to MBP was found in MS patients compared to
healthy subjects [34]. In accordance, Brod and Hood also reported a two-fold increase in T regulator cells (Tregs) in the periphery of MOG-induced C57BL/6 EAE ACTH-fed mice, in comparison to control; hence, ACTH is able to shift the Th1/Th17 CD4+ T cells to the Th2/Treg phenotype [35]. Recently, it has been shown that oral ACTH therapy in EAE caused a reduction in the expression of CD11b+, IL-6, and IL-17 producing lymphocytes in the lamina propria (LP), where the majority of cells involved in immune reactions are located. Indeed, they observed a reduction in IL-17 and IFN-γ, while CD4+ FoxP3+ Treg cell frequency increased [36].

2.1.5 Thyroid-stimulating hormone (TSH) and follicle-stimulating hormone (FSH)

No studies were found concerning TSH and FSH in EAE model.

2.2 Posterior lobe of pituitary

2.2.1 Vasopressin

Induction of EAE does not significantly alter the plasma level of vasopressin. In fact, a single injection with IL-1b in EAE Lewis rats, 1 week prior to immunization with EAE induction emulsion, decreased the severity of EAE; however, it also significantly increased the plasma vasopressin, compared to untreated-EAE rats [27]. In accordance, Ruocco et al. reported an elevated content of the hypothalamic arginine vasopressin in male Lewis EAE rats, compared to controls [31]. Moreover, Quintanar-Stephano et al. showed that administration of desmopressin, an agonist of arginine vasopressin, markedly ameliorates the severity of EAE rats as measured by decreased clinical scores and immune cell infiltration into the spinal cord, suggesting that arginine vasopressin could have an important role in the maintenance of immune competence [29]. A recent study on Lewis rats showed that low levels of vasopressin or inhibition of its receptor by conivaptan, an antagonist, resulted in the reduction in disease severity. This was associated with a decrease in BBB permeability through V1a and V2 vasopressin receptors [37].

2.2.2 Oxytocin

Recently, a study on EAE rats investigated the changes in expression levels of hypothalamic feeding-related peptide genes and neuroendocrine responses and showed an activation in the oxytocinergic pathway as they observed an increase in mRNA and plasma oxytocin in EAE rats [38]. A summary of EAE animal models used to study hormones in the pituitary gland is given in Table 1.

3 Hypothalamus

3.1 Thyrotropin-releasing hormone (TRH)

Early investigation showed that injury in TRH-containing axons occurs early in the development of EAE rats [39]. Later, Brod and Bauer examined whether TRH has therapeutic activity in MS using active and adaptive EAE mouse model [40]. Results revealed that oral administration of TRH markedly ameliorates the severity of EAE scores and symptoms by reducing Th1-like, Th17, and TNF-α cytokines and increasing Th2-like cytokines of IL-13 in spinal cord lymphocytes. Therefore, TRH was introduced as a hormone with therapeutic potential in MS.

3.2 Gonadotropin-releasing hormone (GnRH)

Quintanar et al. investigated the role of GnRH in EAE model since GnRH has neurotrophic properties and the spinal cord possesses GnRH receptor [41]. GnRH therapy considerably reduced the clinical scores of EAE and increased the number of larger area axons in GnRH-EAE rats, compared to untreated-EAE rats. In addition, GnRH-treated EAE rats showed increased levels of expression of neurofilaments NF-68, NF-160, and NF-200 compared to untreated-EAE rats, whereas the latter showed higher NF-68 and NF-160 levels compared to control rats. On the other hand, mice treated with GnRH and Antide, a GnRH receptor antagonist, showed similar areas to the rats without GnRH therapy. Moreover, GnRH* Antide-EAE mice showed similar levels of NFs to untreated-EAE group. Furthermore, Guzman-Soto et al. investigated the role of leuprolide acetate, a GnRH agonist, in EAE model of MS. Results confirmed that leuprolide acetate reduced the severity of EAE scores while significantly increasing the expression of NF-68 and NF-160, compared to untreated-EAE mice [42]. This was coincident with higher levels of MBP protein expression and fewer numbers of infiltrated cells in the spinal cord. Leuprolide acetate seemed to be more efficient than GnRH in inducing the expression
### Table 1: A summary of EAE animal models used for hormones in the pituitary gland

| Tissue | Source | Hormone | Animal and strain of EAE model | Gender | Age       | Immunogen for EAE induction | Reference |
|--------|--------|---------|--------------------------------|--------|-----------|-----------------------------|-----------|
| Anterior lobe | SJL/J mice | Luteinizing hormone (LH) | M & F | 8–12 weeks | PLP139-151 | [13] |
|          | LWS rat  | Prolactin (PRL)          | F     | 60 days    | gpSCH      | [14] |
|          | LWS rat  |                                | M     | NA         | gpSCH      | [15] |
|          | LWS rat  |                                | M     | 6 weeks    | wrSCH      | [17] |
|          | GMM      |                                | F     | 8–12 weeks | MOG35-55   | [18] |
|          | Virgin C57BL/6 mice |                      | F     | 8–10 weeks | MOG35-55   | [19] |
|          | C57BL/6 mice |                          | F     | 6–8 weeks  | MOG35-55   | [20] |
| Growth hormone (GH) | LWS rat |                                | M     | 6 weeks    | wrSCH      | [21] |
|          | GMM      |                                | F     | 6 weeks    | MOG35-55   | [22] |
|          | LWS rat  | Adrenocorticotropic hormone (ACTH) | F     | NA         | gpSCH      | [23] |
|          | LWS rat  |                                | M     | NA         | gpSCH      | [24] |
|          | Sabra rats |                          | M     | NA         | wrSCH      | [25] |
|          | LWS, BN, and DA rats |                  | F     | 8–12 weeks | gpMBP & rrMOG | [26] |
|          | LWS rat  |                                | M     | NA         | gpMBP      | [27] |
|          | LWS rat  |                                | M     | NA         | gpBH       | [28] |
|          | LWS rat  |                                | F     | NA         | gpBH       | [29] |
|          | C57BL/6 mice |                        | F     | 6–9 weeks  | MOG35-55   | [30] |
|          | LWS rat  |                                | M     | 6–8 weeks  | gpMBP      | [31] |
|          | SJL/J mice |                          | F     | 4–6 weeks  | PLP139-151 | [33] |
|          | C57BL/6 mice |                        | F     | 6–8 weeks  | MOG35-55   | [34] |
|          | C57BL/6 mice |                        | F     | 6–8 weeks  | MOG35-55   | [36] |
| Posterior lobe of pituitary | LWS rat | Vasopressin               | M     | NA         | gpMBP      | [27] |
|          | LWS rat  |                                | F     | NA         | gpBH       | [29] |
|          | LWS rat  |                                | M     | 6–8 weeks  | gpMBP      | [31] |
|          | LWS rat  |                                | F     | 10–12 weeks | gpBH      | [37] |
|          | LWS rat  | oxytocin                     | M     | 7 weeks    | gpMBP      | [38] |

**Abbreviations:** gpSCH – guinea pig Spinal Cord Homogenate; gpMBP – guinea pig Myelin Basic Protein; gpBH – guinea pig Brain Homogenate; wrSCH – wistar rat Spinal Cord Homogenate; rrMOG – recombinant rat Myelin Oligodendrocyte Glycoprotein; PLP – Proteolipid Protein; DA – Dark Agouti rats; BN – Brown Norway; SJL/J – Swiss Jackson Laboratory/Jackson mice; GMM – Genetically manipulated mice.
of NFs. Later, leuprolide acetate-treated EAE rats were demonstrated to have a decline in the activation of NF-κB, a transcription factor mainly involved in inflammation, immune response, and cell survival, but also proinflammatory mediators including TNF-α, IL-1β, and IL-17A, in comparison to untreated-EAE rats [43].

3.3 Growth hormone-releasing hormone (GHRH)

The potential involvement of GHRH in the pathogenesis of EAE was addressed using GHRH receptor-deficient mice (Ghrhrt/rt) which showed no clinical symptoms of EAE during the entire period of study [44]. In addition, GHRHR deficiency did not affect the activation of T cells and GHRHR-deficient EAE mice had higher levels of anti-MOG IgG, compared to control, suggesting that resistance of GHRHR−/− mice to EAE could be due to a deficient immune response. Therefore, GHRH plays an important role in the development of EAE and could be a therapeutic target.

3.4 Corticotropin-releasing hormone (CRH)

The hypothalamo-pituitary-adrenal axis (HPA-axis) activity is regulated by CRH and arginine vasopressin (AVP) in the paraventricular nucleus (PVN) of the hypothalamus [45]. Calzà et al. showed a reduction in CRH mRNA levels in the PVN 4 days post EAE induction, which recovered at 10 days but decreased again until day 20, the last day of experiment [46]. In contrast, Huitinga et al. showed unchanged CRH levels in the median eminence of male EAE Lewis rats, compared to controls [27]. On the other hand, CRH-deficient mice were found to be resistant to EAE induction and developed a mild form of EAE [47]. Moreover, administration of Astressin, a specific CRH antagonist, reduced the disease severity in mice. Indeed, CRH’s effects on EAE development were shown to be independent of its glucocorticoid-inducing effect. In addition, results showed that IkBα phosphorylation, which inhibits the NF-κB transcription factor, was decreased in CRH-deficient T cells. Finally, peripheral CRH was suggested to apply its proinflammatory activity in EAE through a selective increase in Th1-type responses.

3.5 Somatostatin (SST)

Muhvic and his colleagues introduced the role of somatostatin in EAE since 1992 [48]. On the other hand, they investigated the effect of the somatostatin analogue SMS 201-995 (octreotide) on EAE in the relatively resistant Albino Oxford (AO) strain of rats [49]. Results showed that the number of EAE-induced rats was higher in somatostatin-treated rats compared to controls. Moreover, the proportion of CD8+ T cells in the popliteal lymph nodes (PLN) decreased in somatostatin-treated rats, in comparison to control, while the proportion of CD25+ cells increased. Therefore, somatostatin increased the susceptibility of AO rats to EAE. In contrast, another study in mice, instead of AO rats, showed that oral somatostatin inhibits EAE [50]. Indeed, the authors showed a reduction of Th1 and Th17 and an induction of Th2-like IL-4 cytokines in the spleen and CNS which caused an inhibition of the disease. Further investigations are needed to clarify the role of somatostatin in EAE.

A summary of EAE animal models used to study hypothalamic hormones is given in Table 2.

4 Pineal gland

4.1 Melatonin

Melatonin was investigated in EAE for the first time by Constantinescu et al., when the effect of luzindole, a melatonin receptor antagonist, was examined [51]. In fact, luzindole inhibited the development of EAE through inhibition of melatonin. Later, several studies showed that EAE severity is reduced by melatonin therapy [52–54]. The reduced level of EAE scores in melatonin-treated group was coincident with lower number of inflammatory cells infiltration (CD4, CD8, NK) into the spinal cord [52]. They also found that only ICAM-1 expression, but not LFA-1a, is considerably decreased by melatonin therapy. Since NK cells play a suppressive role in EAE, it’s suggested that melatonin reduces the severity of EAE through a mechanism involving ICAM-1.

On the other hand, the effects of melatonin therapy on T effector/regulatory responses of EAE showed an increased level of Treg frequency and IL-10 synthesis in the CNS, whereas Th1/Th17 responses in both peripheral and CNS were reduced in melatonin-treated EAE mice [53].
Moreover, melatonin reduced the frequencies of T effector and T central memory cells, and TNF-producing CD4+ cells. In addition, mononuclear infiltration (CD4 and CD11b cells) in the CNS was also reduced by melatonin therapy. This suggested that melatonin ameliorates EAE by controlling both peripheral and central T effector/regulatory responses. Further work by Chen et al. showed, however, that the percentage of sorted splenic dendritic cells and the population of Foxp3+ CD4+ T cells in the spleens were not significantly different between groups [54]. Furthermore, melatonin enhanced splenic IL-10 in regulatory T cells by inducing IL-27 expression in the splenic dendritic cells which suppresses the expression level of IFN-γ, IL-17, IL-6, and CCL20 in the CNS and inhibits antigen-specific T cell proliferation. In line, Ghareghani et al. reported for the first time that the age of EAE models plays a substantial role in melatonin therapy. Indeed, as the administration of melatonin in EAE Lewis rats exacerbated the clinical symptoms of EAE by enhancing the immune cell infiltration into the CNS, demyelinated plaques (low MBP-positive cells) activated astrocytes, serum lactate, and the ratio of IFN-γ/IL-4. Our study on EAE mice showed that melatonin alone or in combination with baclofen reduces clinical scores and demyelination which is associated with an increase in IL-4 and a decrease in IFN-γ serum levels. Furthermore, catalase and superoxide dismutase, as antioxidant enzymes, increased following the treatment, while the oxidative stress-related malondialdehyde levels decreased [56]. We further showed that melatonin therapy modulates cerebral metabolism and enhances remyelination which is associated with an increase in pyruvate dehydrogenase kinase-4 (PDK-4), an enzyme involved in fatty acid synthesis during remyelination, which we believe is a side effect of melatonin therapy [57]. Further studies are needed to determine the precise role of melatonin in the EAE model, especially with respect to age, gender, strain of mice/rats used, and melatonin dosage.

A summary of EAE animal models used to study pineal gland hormones is given in Table 2.
5 Thyroid gland

5.1 Thyroxine (T4)

The effects of thyroid hormones are predominantly mediated by thyroid hormone receptors (THR), which are part of the family of nuclear receptors. The 2 receptor genes THRA and THRB encode the 2 proteins THRα and THRβ, respectively. In addition, each of these genes generates two isoforms (α1-2, β1-2) by alternative splicing. The α isoforms are widely expressed in the fetal brain as well as oligodendrocyte precursor cells (OPCs), while the β isoforms expression is more restricted to differentiated oligodendrocytes with a dramatic increase that starts at birth in the rat [58,59].

Investigating the effect of thyroid hormone (thyroxine, T4) on EAE mice showed that EAE induction caused a sharp increase in the number of Ki-67 and BrdU+ nuclei, a marker of proliferating cells, in the SVZ, white and gray matter of brain and spinal cord, and between ependymal cells in the central canal. Few numbers of Ki-67+ and BrdU+ cells belong to perivascular inflammatory cells and parenchymal glial cells, which are strongly expressed in the acute stage of EAE. In contrast, T4 administration reduced the rate of proliferation and undifferentiated precursors in the spinal cord and SVZ. Moreover, codistribution of Ki-67 and nestin immunoreactivity showed a reduction in the expression of nestin-positive cells in the SVZ. Moreover, they showed that the administration of thyroid hormone in EAE reduces the rate of proliferation, while it favors differentiation towards oligodendrocytes and their maturation; hence, T4 therapy ameliorates the regulation of myelin-forming proteins in EAE model. Importantly, the increased level of MBP in EAE model was found to be caused not only by a direct regulation of MBP gene expression, but also by newly formed oligodendrocytes [60]. The fact that MBP is a target gene for thyroid hormone receptor has been already reported by Farsetti et al. [61].

In line, Gallo and Armstrong reported that the level of nestin protein expression is high in proliferating progenitors, while it declines in differentiated oligodendrocytes [62]. In support of these findings, Lezoualc’h et al. demonstrated that the nestin promoter has a binding site for nuclear receptors, which allows the thyroid hormone to bind nestin in neural progenitor cells of the embryonic CNS [63].

Albornoz et al. induced EAE in the gestated mice under hypothyroidism which already were treated with or without T4. Their findings showed higher clinical score of EAE, demyelination area, immune cell infiltration, the number of CD4+ and CD8+ T cells, percentage of death in oligodendrocytes (labeled with TUNEL) in the spinal cord, and lower expression of myelin basic protein (MBP) of EAE mice gestated in hypothyroid mothers, compared to EAE mice gestated in normal mother. All of these changes reverted when T4 was added during gestation [64]. This suggested that gestational hypothyroidism causes more severe inflammation and demyelination in EAE mice. Given the fact that Nerve Growth Factor [30] drops in acute phase of EAE [46], Calza et al. reported that T4 therapy restored the NGF level. NGF administration showed a beneficial role by diminishing the clinical score of EAE and by protecting oligodendrocytes against injury induced by TNF-α proinflammatory cytokine [65]. Moreover, several studies investigated the role of nuclear hormone receptor superfamily members that are known to affect the immune response, mainly the receptors for retinoids, steroids, and thyroid hormone. Results revealed an expression of the peroxisome proliferator-activated receptors (PPARs) in the inflammatory infiltrate of EAE mice spinal cord. In contrast, administration of PPAR-γ ligand 15d-PGJ2 reduced the severity of EAE by inhibiting the activation and expansion of encephalitogenic T cells, which suggests that PPAR-γ agonists may act as a new therapeutic strategy for MS in which thyroid hormones are most probably involved [66–68]. Furthermore, Fernandez et al. showed that T4 treatment is effective in reducing the severity of the relapse in Lewis, but not Dark Agouti (DA), rats of EAE model. They also showed that T4 favors myelin sheath reconstruction by increasing the mRNA expression levels of platelet-derived growth factor α receptor (PDGFαR) marker of the oligodendrocyte precursor cells (OPC) in the spinal cord of EAE-DA rats on day 18 postimmunization [69]. More details about the role of TH on oligodendrocytes have been reviewed by Calzà et al. [70].

Two types of circulating TH are present: L-iodothyronine (T3), the active form, and tetra-iodothyronine (T4), the precursor of T3. Deiodinase enzymes (D) type 1 and 2 catalyze conversion of T4 to T3, whereas D type 3 (D3) catalyzes inactivation of T4 and T3 into reverse (r)T3 and 3,3-diiodothyronine (T2), respectively [71,72]. Since D3 expression may play an important role in decreasing the local bioavailability of TH at the inflammation sites, Boelen et al. showed that D3 is considerably increased in the inflammatory sites of EAE mice spinal cords [71]. While previous studies reported that most of the cellular effects of T3 are mediated by THRα and THRβ [73,74], Fernández et al. showed that THRα-1 and THRβ-1 mRNA expression are markedly increased in proliferating neurospheres media isolated from SVZ of adult EAE rats; however, THRα-2 expression did not show any significant
changes. Moreover, treatment by T3 increased the expression of oligodendrocyte transcription factor Olig-1, a basic helix–loop–helix (bHLH) transcription factor expressed in cells of the oligodendrocyte lineage, and stimulated oligodendrocytes maturation. Indeed, T3 increases more than 3- and 10-fold the generation of GFAP+ astrocytes and CNPase+ oligodendrocytes when used during proliferation and differentiation conditions [75]. Importantly, this elevated expression of astrocytes favors the conversion of T4 to T3 by D2 and benefits an increased bioavailability of the active T3 and could also be detrimental for myelin repair [72,75].

On the other hand, the effects of T3 on EAE were investigated by D’Intino et al., using the nonhuman primate Callithrix Jacchus (marmoset), instead of EAE mice. Clinical scores of EAE severity were significantly decreased by T3 therapy; however, there was a significant increase in the mRNA expression levels of PDGFα in the spinal cord and MBP in the optic nerve and cerebral cortex of T3-treated EAE group. Moreover, D3, but not D2, mRNA levels were significantly increased by T3 therapy, compared to untreated EAE. While THRβ-1 and THRβ-2 significantly elevated in T3-EAE, THRα-1 and THRα-1 did not show significant changes in response to T3 therapy, compared to EAE [76]. A year later, Dell’Acqua et al. showed that T3 therapy causes a better outcome of clinical and neurophysiological parameters; however, the plasma levels of T3 and T4 did not show significant differences between EAE and EAE-T3 groups on day 39 postimmunization. Indeed, T3 therapy did not affect inflammatory cellular infiltrate, but it strongly suppressed the loss of myelin staining, increased myelination, and did not present any nude axons, compared to untreated EAE. Then, they also demonstrated that the dysregulation of THR expression in the EAE was corrected by T3, as THRα-1 and THRβ expression significantly decreased in T3-treated mice, although THRα-2 showed no significant differences [77]. Finally, Castelo-Branco et al. showed that treatment of MBP63–88-specific T cell lines with T3, prior to transfer to naïve rats to establish passive EAE model, had no effect on T cell proliferation, but significantly decreased the frequency of IL-17-producing cells and increased the expression of C–C chemokine receptor type 7 (Ccr7) and L-selectin (D62L) [78]. CCR7 ligands have a novel function in stimulating the pathogenic Th17 cells in EAE induction through IL-23-dependent generation from dendritic cells [79], while CD62L regulates naïve T cell homing into lymph nodes and the migration of leukocytes to sites of inflammation [80]. Castelo-Branco et al. suggested that T3 has the potential to inhibit lymphocytes migration from lymph nodes into the CNS [78]. Investigation of the adult offsprings gestated in hypothyroxinemia demonstrated that it leads to imprint the immune response and subsequently early appearance of EAE symptoms [81].

### 5.2 Calcitonin (CT)

CT therapy was shown to delay the onset of EAE, while its combination administration with 1,25(OH)2D3 lowered the effective dose required to suppress EAE. Importantly, this combination therapy is dependent on dietary calcium [82]. However, at the molecular level, CT administration does not seem to be a necessary factor for 1,25(OH)2D3-mediated suppression of EAE. Indeed, knock-out mice for CT and calcitonin gene-related peptide-α (CGRP) genes did not change the EAE progression or serum calcium, while administration of 1,25(OH)2D3 significantly ameliorated the EAE severity and enhanced the serum level of calcium [83].

Moreover, it has been reported that SA13353, a novel transient receptor potential vanilloid 1 (TRPV1) agonist, and capsaicin (Cap) elevate the serum level of CGRP [84]. The therapeutic activity of CGRP was then examined by Matsuda et al., using a human CGRP-expressing plasmid transfected to C57BL/6 mouse bone marrow-derived matured DC (mDC) followed by the induction of EAE in this mouse. It was observed that only 50% of mice developed EAE in the CGRP-transfected group, compared with 80% in the mock-transfected group. In addition, cytokines production of IL-10, IL-2, IL-6, IL-17, TNF-α, and IFN-γ from spleen cells of EAE mice increased in CGRP-transfected mice, which was dependent on MOG concentration, compared with the mock-transfected mice. Moreover, the proportion of CD4+ CD25+ Foxp3+ cells increased in the CGRP-transfected mice, suggesting that gene therapy with CGRP-expressing mDC would be a novel strategy to suppress the development of EAE [85].

Since CGRP binds to its specific receptor composed of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) [86], Mikami et al. examined the role of CGRP in EAE using RAMP1-deficient mice. Although a lower EAE score and delayed peak score were observed in RAMP1–/– mice, compared with wild-type, the population of Th17 cells was also decreased in the first group suggesting that CGRP promotes Th17-mediated inflammation by increasing IL-17 and IL-21 production in EAE mice [87]. Finally, CGRP-deficient mice showed aggravated EAE signs, while injection of CGRP into the lumbar CSF decreased EAE severity. Moreover, the production of TNF-α, IFN-γ, IL-17, IL-2, and IL-4 did not demonstrate any alterations in the peripheral
lymphocytes of CGRP-treated mice; however, it reduced microglia transition to bushy morphology. Indeed, the expression of Iba1+ microglia showed slightly more bipolar and less round-fitting morphology in CGRP-treated mice which suggests that CGRP can inhibit microglia activation in EAE [88].

A summary of EAE animal models used to study thyroid hormones is given in Table 3.

### 6 Parathyroid glands

#### 6.1 Parathyroid hormone (PTH)

Given the fact that 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) regulates the calcium level in blood by increasing calcium absorption from the small intestine, releasing calcium from bone, and increasing the reabsorption of calcium in the kidney through a PTH-mediated mechanism, Meehan et al. examined the role of PTH in EAE development [89]. They used a 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mouse which is responsible for the synthesis of 1,25-(OH)2D3. This strain of mice was then treated with PTH to induce hypercalcemia, without changing the circulating levels of 1,25-(OH)2D3. This PTH-mediated hypercalcemia inhibited EAE development in female, but not male mice. In contrast, once hypercalcemia was suppressed by diet, PTH administration no longer prevented EAE, suggesting that hypercalcemia prevented EAE after disease induction in female mice.

A summary of EAE animal models used to study parathyroid gland hormones is given in Table 3.

### 7 Bone

#### 7.1 Osteocalcin (OCN)

It has been reported that the serum level of osteocalcin (OCN) has a negative correlation with the severity of EAE.

| Tissue | Hormone | Animal and strain of EAE model | Gender | Age | Immunogen for EAE induction | Reference |
|--------|---------|--------------------------------|--------|-----|-----------------------------|-----------|
| Thyroid Gland | Thyroxine (T4) | C57BL/6 mice | F | 6–9 weeks | MOG35-55 | [30] |
| | | LWS rat | F | NA | gpSCH | [46] |
| | | LWS rat | F | NA | gpSCH | [60] |
| | | C57BL/6 mice | F | 6–8 weeks | MOG35-55 | [64] |
| | | Callithrix Jacchus (marmoset) | NA | NA | rrMOG | [65] |
| | | GMM | NA | 7–10 weeks | MBP Ac1-11 | [66] |
| | | GMM | NA | NA | MOG35-55 | [68] |
| | | LWS & DA rats | F | NA | gpSCH | [69] |
| | | DA rat | F | 7–8 weeks | rSCH | [71] |
| | | LWS rat | F | 2–3 months | gpSCH | [75] |
| | | Callithrix Jacchus (marmoset) | M & F | 11–144 months | hrMOG1-125 | [76] |
| | | DA rats | F | NA | gpSCH | [77] |
| | | DA/Kini rats | M & F | NA | rMOG1-125 & gpMBP63-88 | [78] |
| | | GMM | NA | NA | MOG35-55 | [79] |
| | | GMM | NA | 5–6 weeks | MBP Ac1-11 | [80] |
| | | C57BL/6 mice | F | 7 weeks | MOG35-55 | [81] |
| | | C57BL/6 mice | F | 9–10 weeks | MOG35-55 | [82] |
| | | C57BL/6 mice | M & F | 8–12 weeks | MOG35-55 | [83] |
| | | C57BL/6 mice | F | 6–8 weeks | MOG35-55 | [85] |
| | | C57BL/6 mice | NA | 6–10 weeks | MOG35-55 | [87] |
| | | C57BL/6, SJL, and GMM mice | F | 7–8 weeks | MOG35-55 | [88] |

| Parathyroid Glands | Parathyroid hormone (PTH) | GMM | M & F | 5–6 weeks | MOG | [89] |

Abbreviations: gpSCH – guinea pig Spinal Cord Homogenate; rSCH – rat Spinal Cord Homogenate; rrMOG – recombinant rat Myelin Oligodendrocyte Glycoprotein; DA – Dark Agouti rats; GMM – Genetically manipulated mice.
Indeed, Ghareghani et al. reported that OCN serum level significantly decreased in EAE model, while medications which ameliorated EAE severity were associated with an increase in osteocalcin [90]. For instance, the serum level of osteocalcin significantly increased in EAE mice treated with cyclosporine A and 1α,25-(OH)₂D₃ (active form of Vitamin D) [91] or melatonin [90], but was insignificantly increased in 1,25(OH)₂D₃-treated EAE mice [92].

### 7.2 Lipocalin 2

Berard et al. used an Affymetrix gene array to track the alterations in the gene encoding Lipocalin 2, involved in matrix metalloproteinase (MMP) stabilization, glial activation, and cellular iron flux [93]. Lipocalin 2 gene expression increased in monocytes and reactive astrocytes by about 60-fold at the onset of EAE, while its receptor 24p3R was also shown to be expressed by monocytes, macrophages/microglia. Importantly, Lipocalin 2-deficient mice showed more severe EAE, in comparison to wild-type mice. In accordance, another study by Nam et al. demonstrated that EAE has been suppressed in Lipocalin 2−/− mice [94]. In addition, Lipocalin 2-treated glial cells, isolated from Lipocalin 2−/− EAE mice, had higher levels of proinflammatory cytokines, MMP-9, and chemokines. These findings highlighted that Lipocalin 2 is a critical mediator of autoimmune inflammation in EAE pathogenesis. Some pharmacological studies examined the effect of EAE medications on the expression of Lipocalin 2. For instance, increased levels of Lipocalin 2 were seen at active phases, onset and relapse, in blood-CSF sample as well as choroid plexus (CP) of EAE mice [95]; however, administration of Natalizumab, a well-known medication for MS [96], ameliorated the severity of EAE by modulating and normalizing CSF Lipocalin 2, while markedly reducing its astrocytic expression. Similarly, Ebrahimi-Kalan et al. showed the inhibitory effect of MS14, an herbal-marine drug with anti-inflammatory activity, on the severity of EAE through reduction of Lipocalin 2 [97].

### 7.3 Erythropoietin (EPO)

The neuroprotective role of erythropoietin in EAE was shown for the first time by Brines and colleagues who administrated the recombinant human erythropoietin (r-Hu-EPO), 3 days after immunization until day 18, causing a delay in EAE onset and reduction of peak clinical scores, in comparison to untreated-EAE rats [98]. It is well-known that astrocytes and microglia play a substantial role in MS progression, as activated and proliferating forms of these cells have been observed in demyelinated areas [99]. Agnello and colleagues reported that EPO considerably reduces both glial proliferation and activation and subsequently diminishes inflammation through reducing spinal cord TNF-α and IL-6 [100]. Importantly, Li and colleagues reported that erythropoietin also reduces the blood-brain barrier (BBB) leakage and major histocompatibility complex class II (MHC-II) in the spinal cord [101]. This reduced level of MHC-II was further observed by Zhang et al., who demonstrated that EPO suppresses the levels of IFN-γ and IL-17 both in peripheral splenic cells and CNS-infiltrating cells [102]. Similarly, it was shown that EPO improved neurological functional recovery in EAE mice by increasing the level of BDNF* cells and proliferation of oligodendrocyte progenitor cells (OPCs), stimulating oligodendrogenesis, and by diminishing proinflammatory infiltration [103]. In line, combination therapy of methotrexate and EPO revealed a stimulating effect on oligodendrogenesis [104].

On the other hand, to clarify the best time of EPO administration in EAE, Savino and colleagues [105] showed that EPO therapy works in all stages of EAE; however, its efficiency is reduced once it is administrated late, 15 days after the onset of symptoms. The effects of EPO on hematocrit and EAE pathological outcomes were investigated by Yuan et al., using truncated small linear or cyclic EPO-derived peptides from various domains of the full-length EPO [106]. The 19-mer JM-4 peptide showed the best potential to treat EAE without producing hematocrit alterations in EAE mice, similar to the full-length EPO, and modulated immune/inflammatory reaction in EAE. EPO induces its neuroprotective role via signaling to several critical subsets of immune cells residing in the peripheral lymphatic system. Indeed, EPO reduced the proliferation of MOG-specific T cells in vitro, suppressed T cell cytokine production, reduced the total number of mononuclear and T cells in EAE peripheral lymph nodes, increased the expansion of peripheral Tregs, and inhibited the polarization of Th17 cells in EAE mice.

It has been shown that expression of the inhibitor of metalloproteases (TIMPs) is increased in astrocytes forming the BBB and surrounding demyelinated area [107], while TIMP-1-deficient mice have elevated levels of demyelination and microglial activation in EAE mice [108]. Thorne et al. showed that darbepoetin alfa therapy, an EPO analogue, reduced the clinical scores of EAE mice, accompanied with an increased number of TIMP-1-expressing astrocytes, both in the brain and spinal cord [109]. Although TIMP-1-deficient mice showed severe
EAE outcomes, compared to wild-type, darbepoetin alfa therapy could not affect EAE severity in TIMP-1−/− mice, highlighting TIMP-1 importance in EPO therapy of EAE. Similarly, ARA290, a nonerythropoietic analogue, has been shown to considerably ameliorate the severity of EAE [110]. In accordance, the expression of EPO was shown to be induced in spinal cord of EAE mice, clearly localized to motor neurons, and the authors suggested that EPO should be viewed as part of the inflammatory/anti-inflammatory network in MS [111]. On the other hand, EPO therapy in EAE mice induced endogenous heme oxygenase-1 (HO-1), an anti-oxidative stress protein, a possible factor in diminishing the inflammatory responses involved in EAE [112]. Recently, Moransard et al. used transgenic mouse strains to investigate whether EPO primarily applies its effects in the CNS or the periphery [113]. Although EAE onset did not differ between control and two transgenic EAE mice with overexpressed r-Hu-EPO either in CNS only (tg21) or systemically (tg6), their progression markedly increased in transgenic mice compared to controls. However, no peripheral immunomodulatory effects were seen in tg21 strain whose modulation was limited to a reduction in CNS macrophages. In contrast, macrophages were upregulated in the CNS, but not the periphery, of tg6 strain.

On the other hand, Sattler et al. showed on EAE mice that EPO promotes the survival and function of retinal ganglion cells (RGCs), the neurons that form the axons of the optic nerve, through three independent intracellular signaling pathways of p-Akt, p-MAPK 1 and 2, and Bcl-2 [114]. In accordance, the work by Diem and colleagues revealed that coadministration of EPO and high dose methylprednisolone, a steroid medication in MS, had relatively higher potential to induce neuroprotection in RGCs and optic nerves, compared to respective mono-therapies [115].

Long-term effects of EPO were investigated, for the first time, by treating EAE mice using JM4, an EPO-derived small peptide, which is free from any side effects. Following 12 days of JM4 therapy, they observed a reduction in disease severity after day 60 until day 100 post-immunization [116].

7.4 FGF-23 (phosphatonin)

No studies were found concerning FGF-23 in EAE model.

A summary of EAE animal models used to study bone hormones is given in Table 4.

Table 4: A summary of EAE animal models used for hormones in the bone

| Tissue       | Hormone       | Animal and strain of EAE model | Gender | Age          | Immunogen for EAE induction | Reference |
|--------------|---------------|--------------------------------|--------|--------------|----------------------------|-----------|
| Bone         | Osteocalcin (OCN) | CS7BL/6 mice                   | F      | 6–8 weeks    | MOG35-55                  | [90]      |
|              |               | SJL/ola mice                   | M      | NA           | MSC                       | [91]      |
| Lipocalin 2  |               | SJL mice                       | F      | 8–10 weeks   | PLP139–151                | [92]      |
|              |               | GMM                            | F      | 8–11 weeks   | MOG35–55                  | [93]      |
| Erythropoietin (EPO) | | GMM                            | NA     | 7–8 weeks    | MOG35–55                  | [94]      |
|              |               | SJL mice                       | F      | 6–8 weeks    | PLP139–151                | [95]      |
| Lipocalin 2  |               | CS7BL/6 mice                   | F      | 8–10 weeks   | MOG35–55                  | [97]      |
|              |               | C57BL/6 mice                   | F      | 6–8 weeks    | MBP                       | [98]      |
| Lipocalin 2  |               | LWS rat                        | F      | 6–8 weeks    | gpMBP                     | [100]     |
| Lipocalin 2  |               | C57BL/6 mice                   | F      | 8–14 weeks   | MOG35–55                  | [101]     |
| Lipocalin 2  |               | C57BL/6 mice                   | F      | 8–10 weeks   | MOG35–55                  | [102]     |
| Lipocalin 2  |               | SJL/ola mice                   | F      | 8–10 weeks   | PLP139–151                | [103]     |
| Lipocalin 2  |               | CS7BL/6 mice                   | F      | NA           | MBP                       | [104]     |
| Lipocalin 2  |               | CS7BL/6 mice                   | F      | 6–8 weeks    | MOG35–55                  | [105]     |
| Lipocalin 2  |               | SJL & CS7BL/6 mice             | F      | 6–8 & 8–10 weeks | PLP139–151 & MOG35–55  | [106]     |
| Lipocalin 2  |               | GMM                            | M & F  | Adult        | MOG35–55                  | [109]     |
| Lipocalin 2  |               | LWS rat                        | M      | 8–12 weeks   | MBP68–84                  | [110]     |
| Lipocalin 2  |               | CS7BL/6 mice                   | F      | 6–8 weeks    | PLP139–151                | [111]     |
| Lipocalin 2  |               | CS7BL/6 mice                   | NA     | 6–8 weeks    | MOG35–55                  | [112]     |
| Lipocalin 2  |               | GMM                            | M & F  | 8–12 weeks   | MOG35–55                  | [113]     |
| Lipocalin 2  |               | BN rats                        | F      | 8–10 weeks   | rMOG                      | [114,115] |
| Lipocalin 2  |               | SJL/ola mice                   | F      | 8–10 weeks   | PLP139–151 or MOG35–55    | [116]     |

Abbreviations: gpMBP – guinea pig Myelin Basic Protein; MSC – Mouse Spinal Cord; rMOG – recombinant rat Myelin Oligodendrocyte Glycoprotein; PLP – Proteolipid Protein; BN – Brown Norway; SJL/ola – Swiss Jackson Laboratory/Jackson mice; GMM – Genetically manipulated mice.
8 The adrenal glands

8.1 Adrenal cortex

8.1.1 Glucocorticoids (e.g., cortisol)

Several studies have shown that EAE is accompanied by a reduction in the intensity of cortisol metabolism under conditions of in situ perfusion of the liver by solutions containing cortisol in different concentrations as well as in lymphocytes from the cervical lymph nodes of guinea pigs [117–119].

8.1.2 Mineralocorticoids (e.g., aldosterone)

Herrada and colleagues demonstrated that administration of deoxycorticosterone acetate (DOCA), a stable mineralocorticoid analogue of aldosterone, leads to an exacerbation of EAE severity through promotion of Th17 immunity. It is well-known that high levels of aldosterone lead to hypertension and cardiovascular disease where T cell immunity is involved [120].

8.2 Adrenal medulla

8.2.1 Adrenaline (epinephrine)

Wesselmann and colleagues investigated splenic catecholamine in EAE and showed that elevated concentrations of epinephrine were not statistically significant, compared to controls [121]. Since epinephrine action is mediated by β adrenergic receptors, an antagonist of β adrenergic receptors called nadolol was used in EAE model and it was found that the suppression of epinephrine did not affect the clinical outcomes of EAE [122]. The function of epinephrine was recently further investigated by Yan and colleagues. They observed a high expression of the rate-limiting enzyme of epinephrine synthesis, phenylethanol N-methyltransferase (PNMT), in tissue-resident TH17 cells of EAE mice, not in other effector T cell subsets or regulatory T cells. They used a knockout mouse model for PNMT expressing immune cells. Although they observed a lower level of immune cell infiltration in these mice compared to normal EAE mice, the clinical scores did not show significant differences [123].

8.2.2 Noradrenaline (norepinephrine)

White and colleagues showed that norepinephrine decreased sharply in the spinal cord of EAE rats, especially in the lumbar region [124]. In addition, norepinephrine depletion was more evident in lumbosacral and craniothoracal region of spinal cord EAE rats [125]. In contrast, development of acute EAE was suppressed by administration of neurotransmitter-depleting agents [126]. Indeed, depletion of norepinephrine using 6-hydroxydopamine suppressed EAE possibly through deletion of effector amplification mechanism and/or triggering a T suppressor cell mechanism [127]. However, another study suggested that this observation could be due to alteration in the blood-spinal cord barrier function and/or CNS blood flow [128]. In contrast, a study demonstrated that selective elevation of CNS NA levels could provide benefits in EAE, as increasing the norepinephrine levels using atomoxetine, a norepinephrine reuptake inhibitor, or 1-threo-3,4-dihydroxyphenylserine (1-DOPS), a synthetic norepinephrine precursor, did not affect clinical scores and prevented further worsening of EAE, respectively [129]. In addition, Polak and colleagues suggested that raising norepinephrine levels is an efficient method to treat EAE and MS [130]. It is well-known that the primary source of norepinephrine are tyrosine hydroxylase-positive neurons in the Locus coeruleus, and that dysregulation of neurons was observed in EAE and MS. Therefore, Vindeburnol was selectively used to increase Locus coeruleus neuronal viability or activity which resulted in a reduction in astrocyte activation in the Locus coeruleus, hypertrophy of tyrosine hydroxylase-positive neurons, and elevation in spinal cord content of norepinephrine and genes involved in Locus coeruleus survival and maturation [131].

Moreover, Leonard et al. reported an inverse correlation between hypothalamic norepinephrine and corticosterone serum level, both at the peak clinical scores of EAE and in norepinephrine-depleted peripheral nervous system EAE mice [132]. However, a direct correlation was found between corticosterone serum levels and EAE severity, while the striatum showed no change in its content of norepinephrine in EAE mice [133]. Finally, Shaked and colleagues suggested that the transcription factor Nr4a1 regulates the production of norepinephrine in macrophages, as Nr4a1-deficient myeloid cells in mice led to an increase in norepinephrine and EAE severity [134]. In contrast, myeloid-specific deletion of tyrosine hydroxylase, the rate-limiting enzyme in norepinephrine production, demonstrated a protective role against EAE. Although males have a stronger sympathetic nervous
system, Vujnović and colleagues reported that β-adrenoceptor-mediated signaling plays a key role in sexual dimorphism in primary CD4+ T-cell responses in EAE rats. Indeed, rats treated with Propranolol, a nonselective β-adrenergic receptor antagonist, showed higher noradrenaline concentration in draining lymph node (dLN) in males, compared to females [135]. Furthermore, they did another study on α1-adrenoceptor and suggested that this receptor is also involved in interactions between subtypes of CD4+ T cells and antigen-presenting cells [136].

A summary of EAE animal models used to study adrenal gland hormones is given in Table 5.

### 9 Stomach, pancreas, and intestine

#### 9.1 Cholecystokinin (CCK)

The therapeutic potential of GB-115 compound (N-phenylhexanoyl-glycyl-L-tryptophan amide), a dipeptide cholecystokinin receptor antagonist, was demonstrated by suppression of ROS production, improved spontaneous locomotor activity, and reduced edema and neutrophil infiltration of the perivascular space of the brain [137].

#### 9.2 Neuropeptide Y

The role of neuropeptide-Y in EAE was first reported by Bedoui and colleagues [138]. Neuropeptide-Y decreases the susceptibility of mice to EAE induction and was shown to exert its pleiotropic functions via the activation of several G-protein coupled receptor subtypes such as Y(1) receptor, but not Y(5). Moreover, EAE induction was facilitated by administration of Y(1) receptor antagonist. In contrast, the immunomodulatory action of neuropeptide-Y in DA EAE rats showed that CD28 and CD80/CD86 costimulatory molecules acted as a target for neuropeptide-Y-mediated amelioration in EAE through Y(2) and Y(5) receptors [139]. Moreover, Brod and Bauer showed that ingested (oral) neuropeptide-Y inhibits CNS inflammation in EAE mice by diminishing Th17 and Th1-like cytokines and elevating Th2-like cytokines within the CNS [140].

#### 9.3 Ghrelin

Theil et al. examined the role of ghrelin in EAE pathogenesis and showed that although its administration...
ameliorates the severity of EAE clinical scores, it had no beneficial effect in reducing the numbers of inflammatory cells in the spinal cord [141]. Indeed, this has been determined by counting the number of NK cells (NK1.1+/CD3-), B cells (CD19+), NK T cells (NK1.1+/CD3+), macrophages (F4/80+), and CD25+ FOPX3+ cells (in the CD4+ T cell population) in the spinal cord lesions. Theil et al. suggested that monocytes could be potential targets in the ghrelin-mediated EAE inhibition. While the levels of TNF-α, IL-1β, and IL-6 significantly decreased in the spinal cord of ghrelin-treated mice, only TNF-α mRNA levels decreased in their spleens, whereas no significant changes were seen in any of the cytokines in the lymph node or thymus of ghrelin-treated mice. To investigate which cells were important in the ghrelin-mediated suppression of EAE, mRNA levels of IL-1β, IL-6, and TNF-α were assessed in macrophages, microglia, and T cells; however, they only showed marked changes in microglia, suggesting that it might play a key role in ghrelin-mediated suppression of EAE. The effect of ghrelin was further investigated by Liu and colleagues who observed a reduction in the levels of inflammatory cytokines and factors involved in NLRP3 inflammasome signaling and Pyroptosis [142].

9.4 Serotonin

An early study demonstrated that a segment of MBP is composed of one of the 5-hydroxytryptamine (5-HT; serotonin) receptors in the CNS which played an important role in EAE [143]. Later, it was reported that CNS 5-HT neurotransmission is impaired in EAE rats with hind limb paralysis [144] which was correlated with motor deficits manifested during the acute paralytic stage of EAE [145]. In line, administration of some drugs led to modifications in endogenous serotonin levels within the body. Treatment of EAE guinea pigs with serotonin suppressor, especially the antihypertensive medication reserpine, led to quick death of EAE animals. However, serotonin enhancer medication, particularly imipramine hydrochloride antidepressant, showed better survival, even longer than controls [146]. Moreover, using serotonin antagonist and inactivation of neurogenic 5-HT receptors significantly reduced the severity of EAE [147–150]. In contrast, the serotonin antagonist Methysergide did not inhibit the severity of EAE in rabbits when administrated 6 days postimmunization [151].

On the other hand, it was reported that serotonin axons were swollen and distorted at early stages of EAE and get worse when neurological scores increase. Interestingly, the severity of axonal damage correlated with the severity of inflammation and the injured axons were located adjacent to blood vessels or the pial surface, sites at which inflammation occurs during EAE [39]. Moreover, reduced levels of serotonin and the serotonin metabolite, 5-hydroxyindoleacetic acid, were shown in EAE rats which suggested that the reduction is probably a consequence of the damage to descending 5-HT axons [152]. Another study reported that factors associated with spinal cord inflammation may be responsible for the bulbospinal monoaminergic axonal damage in EAE. Indeed, prazosin therapy, an alpha 1-adrenergic antagonist, reduced EAE severity and pathological outcomes [153].

Preventive and therapeutic outcomes were found for antidepressant drugs on EAE such as the use of selective serotonin/norepinephrine reuptake inhibitors (SNRI) sertraline [154], fluoxetine [155,156], and fluvoxamine [157]. Also, immunomodulatory effects of antipsychotic agents were reported in EAE such as the use of risperidone, known to antagonize serotonin 5-HT2A receptors [158], and clozapine [159]. Moreover, monoamine oxidase inhibitor phenelzine therapy, an antidepressant and anxiolytic drug, was reported as an efficient strategy to ameliorate EAE severity [160,161]. Furthermore, attenuation of EAE was shown in mice lacking the 5-HT transporter (5-HTT), which was more prominent in females [162]. Finally, elevated levels of serotonin were found in the brain striatum of EAE mice [133].

9.5 Amylin, secretin, fibroblast growth factor 19, PYY3-36, and incretins

No studies were found concerning the above hormones in EAE model.

A summary of EAE animal models used to study hormones of the stomach, pancreas, and intestine is given in Table 6.

10 Liver

10.1 Insulin-like growth factor-1 (IGF-1)

Liu and colleagues showed that the levels of IGF-1 and GFAP, an astrocytic marker, are elevated in demyelination
areas in EAE model [163]. These astrocytes co-expressed IGF-I with IGFBP-2, a member of the six IGF binding proteins that modulate IGF-1 actions, suggesting that astrocytic expression of IGF-1-related peptides could reduce the immune-mediated demyelination. Indeed, another study reported that IGF-1-induced reductions in immune cell responses can occur even in the absence of demyelination [164]. Similar studies further reported the beneficial role of IGF-1 in EAE and suggested that IGF-1 therapeutic activity is mediated by reducing EAE-induced blood-spinal cord barrier changes, modifying oligodendrocytes to increase myelin regeneration [165–167]. Using in vivo three-dimensional MR microscopy imaging technique, IGF-1 was shown to reflect changes in stabilization or permeability of BBB and/or cell membranes to ameliorate EAE [168]. On the other hand, it has been suggested that coadministration of IGF-1 and IGFBP3 can enhance the efficiency of IGF-1 therapy in EAE [169].

In contrast, Cannella and colleagues were doubtful of IGF-1 being a good therapeutic agent in MS as they showed that administration of IGF-1 at different time points during the acute and chronic phases of EAE had different outcomes and even failed to enhance CNS myelin repair in EAE [170]. Similarly, Bilbao et al. showed that not only administration of recombinant human IGF-1 (rhIGF-1) stimulates regulatory T cells in culture, but it also ameliorates the severity of EAE. Indeed, they indicated that existence and function of IGF-1 receptor are the necessary factors to induce IGF-1 stimulatory effect on regulatory T cell proliferation [171]. In accordance, Genoud and colleagues showed that adeno-associated virus (AAV)-mediated delivery of IGF-1 in the spinal

Table 6: A summary of EAE animal models used for hormones in stomach, pancreas, and intestine

| Tissue                      | Hormone                  | Animal and strain of EAE model | Gender | Age           | Immunogen for EAE induction | Reference |
|-----------------------------|--------------------------|---------------------------------|--------|---------------|-----------------------------|-----------|
| Stomach, Pancreas, and Intestine | Cholecystokinin (CCK) Neuropeptide Y | C57Bl/6 mice F 5–6 weeks | MOG35 | [137]         |                             |           |
|                             |                          | C57Bl/6 & SJL/J mice F 6–10 weeks | MOG35 & PLP139151 | [138]     |                             |           |
|                             |                          | DA rat M 7 months | gpSCH | [139]         |                             |           |
|                             |                          | C57BL/6 F 6–8 weeks | MOG35 | [140]         |                             |           |
|                             |                          | B6 mice F 6–10 weeks | MOG35 | [141]         |                             |           |
|                             |                          | CD rat F NA | gpSCH | [142]         |                             |           |
|                             |                          | LWS rat M NA | lrSCH | [39,152,153] |                             |           |
|                             |                          | Guinea pigs NA Young adult | bBH | [143]         |                             |           |
|                             |                          | CRW-L rats M NA | w-lrSCH | [144]       |                             |           |
|                             |                          | guinea pigs NA NA | gpMBP | [146,148]    |                             |           |
|                             |                          | LWS rat F NA | gpBH | [149]         |                             |           |
|                             |                          | LWS rat M NA | gpMBP | [150]         |                             |           |
|                             |                          | White rabbits F Adult | rSCH | [151]         |                             |           |
|                             |                          | C57/bl mice F NA | MOG | [154]         |                             |           |
|                             |                          | WSR rats F 6–8 weeks | gpSCH | [155]        |                             |           |
|                             |                          | SJL/J mice F 8–10 weeks | MBP AC1-11 & PLP139-151 | [156] | [137]         |           |
|                             |                          | LWS rat F 8–12 weeks | gpSCH | [157]         |                             |           |
|                             |                          | C57BL/6 mice F 8–12 weeks | MOG35 | [158,159]    |                             |           |
|                             |                          | C57BL mice F NA 2–5 months | MOG35 | [160,161]    |                             | [162]    |
|                             |                          | C57BL/6 mice M & F 8–12 weeks | MOG & MOG | [133] | [137]         |           |
|                             |                          | C57Bl mice M 8–12 weeks | MOG | [133]         |                             |           |

Abbreviations: gpSCH – guinea pig Spinal Cord Homogenate; gpBH – guinea pig Brain Homogenate; lrSCH – lewis rat Spinal Cord Homogenate; w-lrSCH – wistar-lewis rats Spinal Cord Homogenate; bBH – bovine Brain Homogenate; rSCH – rat Spinal Cord Homogenate; PLP – Proteolipid Protein; DA – Dark Agouti rats; CRW-L – Charles River Wistar-Lewis rats; WSR – wistar rat; SJL/J – Swiss Jackson Laboratory/Jackson mouse.
cord had no effect on EAE and even worsened the disease when injected after EAE induction [172]. Considering the fact that Th17 and Treg cells balance is disrupted in MS, which play a critical role in immune tolerance, DiToro and colleagues showed that increased aerobic glycolysis following activation of IGF1R leads to a higher Th17 cell differentiation than Treg cells, resulting in an increase in proinflammatory cytokines [173].

10.2 Thrombopoietin (TPO)

Although TPO, a hematopoietic growth factor, induced an increase in the number of white blood cells in TPO-treated EAE mice, the clinical scores of EAE severity did not differ either after immunization or after the disease reached its peak [174]. The mechanism of TPO’s effect on the immune response of EAE remains unknown.

10.3 Hepcidin

Iron accumulates in the CNS of MS patients and in EAE models [175,176]. Iron efflux from cells is mediated by the multi-pass membrane transporter ferroportin (Fpn) which is regulated posttranscriptionally by hepcidin, thus reducing iron efflux and leading to iron accumulation. Zarruk et al. showed that iron and ferritin elevation in the CNS of EAE mice was coincident with about 5-fold hepcidin mRNA increase at all stages of chronic and at the peak of relapsing-remitting EAE [177]. In addition, hepcidin was found in infiltrating macrophages as early as the onset stage in chronic EAE, suggesting that hepcidin-mediated internalization of the Fpn and disruption of iron efflux could be the cause of iron accumulation in macrophages/microglia. In accordance, Čurko-Cofek et al. revealed that chronic iron accumulation affects the clinical course of DA EAE model and accelerated the onset of EAE; however, it accelerated the progression and severity of EAE in male rats [178]. This difference could be due to the variations in the expression of stress response proteins hepcidin and metallothioneins in female and male iron overloaded rats.

10.4 Angiotensinogen and betatrophin

No studies were found concerning these hormones in EAE model.

A summary of EAE animal models used to study liver hormones is given in Table 7.

11 Fat cells (adipocytes)

11.1 Leptin

Matarese et al. used female C57BL/6J wild-type and leptin-deficient (ob/ob) mice to study the influence of leptin on EAE, with or without leptin replacement [179]. They showed that leptin plays a key role in the induction and development of EAE, as leptin-deficient mice were resistant to EAE induction; however, administration of recombinant leptin caused susceptibility to EAE induction and an increase in IFN-γ levels, accompanied by modifying Th1 proinflammatory immune responses and consequent reversal of Ig subclass production. Moreover, these observations were confirmed in a different type of EAE model using SJL (H-2s) female mice in which leptin treatment, before or after EAE onset, significantly exacerbated the disease [180]. In accordance, it was further demonstrated that blocking leptin with antibodies or with a soluble mouse leptin receptor chimera ameliorates the severity of EAE symptoms [181].

On the other hand, the effects of leptin on the kinetics of two models of chronic-progressive and relapsing-remitting EAE, using C57BL/6 (H-2b) and SJL/J (H-2s) mice strains, respectively, were investigated by Sanna et al. Results suggested that leptin is required for the induction and development of proinflammatory response in EAE. Hence, the authors introduced the modulation of leptin-mediated inflammation as an innovative therapeutic achievement particularly in the treatment of Th1 autoimmune diseases including MS. Moreover, histamine receptors type 3 (H3R) is involved in leptin action since H3R-deficient mice developed an obese phenotype related to increased levels of leptin [182]. Therefore, Musio et al. used HDC-deficient mice, which are unable to synthesize histamine, and showed that leptin levels were elevated, suggesting that histamine receptors are involved in regulating autoimmunity in the EAE, in which leptin plays a key role [183].

As shown above, conflicting studies exist about the role of leptin in EAE, being detrimental or beneficial. Recently, Wu et al. demonstrated that EAE is associated with a sharp increase in leptin receptor (ObR) in the reactive astrocytes of hippocampus and hypothalamus [184]. Astrocyte-specific GFAP mRNA and protein were both increased; however, ObRa mRNA was elevated only after resolution of EAE symptoms, whereas ObRb mRNA was decreased at the peak of EAE. Indeed, regulation of LepR mRNA in the hippocampus is subtype-specific with a late increase of LepRa that lags behind the increase of protein...
Table 7: A summary of EAE animal models used for hormones in the liver and fat cells (adipocytes)

| Tissue           | Hormone                        | Animal and strain of EAE model | Gender | Age      | Immunogen for EAE induction | Reference |
|------------------|--------------------------------|--------------------------------|--------|----------|------------------------------|-----------|
| Liver            | Insulin-like growth factor-1 (IGF-1) | LWS rat                        | M      | NA       | gpSCH                        | [163,165–167] |
|                  |                                | (P * SJL)F1 mice                | NA     | 8–10 weeks| gpMBP                        | [169]     |
|                  |                                | SJL/J mice                      | F      | 5–12 weeks| MBP                          | [170]     |
|                  |                                | C57BL/6 mice                    | NA     | NA       | MOG35-55                     | [172]     |
|                  |                                | C57BL/6 mice                    | F      | 5–12 weeks| MOG35-55                     | [173]     |
|                  | Thrombopoietin (TPO)           | SJL/J mice                      | F      | 5–6 weeks | PLP139-151                   | [174]     |
|                  | Hepcidin                       | C57BL/6 mice                    | F      | 8–10 weeks| MOG35-55                     | [177]     |
|                  |                                | DA rats                         | M & F  | 7–8 weeks | bBH                          | [178]     |
| Fat cells (adipocytes) | Leptin                        | GMM                            | F      | 8–10 weeks| MOG35-55                     | [179]     |
|                  |                                | SJL/J mice                      | M & F  | 4–6 weeks | PLP139-151                   | [180]     |
|                  |                                | SJL/J mice                      | F      | 6–8 weeks | PLP139-151                   | [181]     |
|                  |                                | GMM                            | F      | 8–12 weeks| MOG35-55                     | [183]     |
|                  |                                | SJL/J mice                      | F      | 6 weeks   | PLP139-151                   | [184]     |
|                  |                                | GMM                            | F      | 8–10 weeks| MOG79-96                     | [185]     |
|                  |                                | GMM                            | F      | 8–10 weeks| MOG35-55                     | [186]     |
|                  |                                | SJL/J & C57BL/6J mice           | F      | 10 weeks  | PLP139-151 & MOG35-55        | [187]     |
|                  |                                | C57BL/6J mice                   | NA     | 8–10 weeks| MOG                          | [188]     |
|                  | Adiponectin                     | GMM                            | NA     | NA       | MOG35-55                     | [189]     |
|                  |                                | GMM                            | F      | 6–8 weeks | MOG35-55                     | [190]     |

Abbreviations: gpSCH – guinea pig Spinal Cord Homogenate; bBH – bovine Brain Homogenate; PLP – Proteolipid Protein; DA – Dark Agouti rats; SJL/J – Swiss Jackson Laboratory/Jackson mice; GMM – Genetically manipulated mice.
expression and a transient reduction of LepRb during the peak of the disease. In contrast, Mishra et al. showed that astrocytic leptin signaling plays a beneficial role in reducing disease severity [185]. Indeed, astrocyte-specific leptin receptor knockout mice had severe EAE symptoms, compared to wild-type, suggesting that astrocytic leptin signaling serves as a beneficial factor in clearing the infiltrating leukocytes and decreasing autoimmune destruction of the CNS. In accordance, endothelial leptin signaling in EAE showed that removal of leptin signaling, using endothelial leptin receptor-specific knockout mice, reduced EAE severity which emphasized that endothelial leptin signaling increases BBB dysfunction to exacerbate EAE [186].

Calorie-restriction or fasting improved EAE severity, which was concomitant with lower levels of leptin [187]. In order to study the role of energy in EAE development, hypoleptinemia was induced by keeping the mice in a fasting situation, with or without leptin injections for 48 h at the onset of EAE [188]. Fasted mice showed lower EAE clinical scores, compared to control-fed mice. Moreover, fasted mice receiving leptin injection during this period had more severe EAE symptoms than fasted mice without leptin injection. These observations demonstrated that leptin alone can reverse the protection against autoimmunity seen during fasting.

11.2 Adiponectin

Piccio et al. reported for the first time that adiponectin confers a neuroprotective role in EAE [189]. Indeed, adiponectin-deficient mice were used to induce EAE and showed that lack of adiponectin exacerbates EAE severity by inducing higher CNS inflammation, demyelination, and axonal injury. In fact, lack of adiponectin directly affects immune responses, by promoting T cell responses to antigen while Th1 profile was prominent. Moreover, adiponectin receptors 1 and 2 were found to be markedly expressed by murine lymph node cells and splenocytes. In the absence of adiponectin and in response to anti-CD3 stimulation, increased proliferation of ADPKO CD4+ T cell was obtained. Complementary to this study, Zhang et al. revealed the role and mechanism of adiponectin on pathogenic Th17 cells [190]. They reported that adiponectin-deficient mice enhance both Th1 and Th17 cell cytokines in the peripheral immune system and CNS of EAE mice as well as upregulated PPARγ and sirtuin 1 (SIRT1) and suppressed retinoid-related orphan receptor-γt (RORγt), a key transcription factor during the differentiation of Th17 cells. These results suggested that adiponectin modulates the immune response in EAE by inhibiting Th17 cell-mediated autoimmune CNS inflammation.

11.3 Betatrophin, retinol binding protein 4, and asprosin

No studies were found concerning these hormones in EAE model.

A summary of EAE animal models used to study hormones of the fat cells (adipocytes) is given in Table 7.

12 Conclusion

Based on investigations carried out on the endocrine system and EAE, most hormones show conflicting roles in susceptibility to EAE and on therapeutic targets for EAE. This could be due, among others, to different factors such as sampling in different phases of EAE progression, sex, age, strain of mice/rat models used, the type of EAE induction, and the concentration of hormones in therapeutic studies. While some studies reported the beneficial role of melatonin in EAE amelioration, others showed opposite and conflicting results and reported age- and dose-dependent response of EAE models to melatonin therapy. Indeed, it is suggested that the timing of melatonin administration leads to different outcomes in EAE. We strongly believe that studies on the endocrine system in EAE are still at their beginning and we are far away from understanding the role of hormones in EAE susceptibility; hence, further studies are required. New studies should consider the above-mentioned factors to achieve more precise results. For example, hormones or their receptor’s agonists/antagonists should be administered at different times of day/night, at different physiological and pharmacological doses, use mice or rats at different ages, and study the effects at different stages of EAE. This also can be considered for the studies investigating the effect of EAE induction on endocrine system function.

Funding information: Authors state no funding involved.

Conflict of interest: Authors state no conflict of interest.

Data availability statement: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References

[1] Garcia-Reyero N. The clandestine organs of the endocrine system. Gen Comp Endocrinol. 2018 Feb;257:264–71.
[2] Yu J. Endocrine disorders and the neurologic manifestations. Ann Pediatr Endocrinol Metab. 2014 Dec;19(4):184–90.
[3] ThyagaRajan S, Priyanka HP. Bidirectional communication between the neuroendocrine system and the immune system: relevance to health and diseases. Ann Neurosci. 2012 Jan;19(1):40–6.
[4] Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 Sep;343(13):938–52.
[5] Iwanowski P, Losy J. Immunological differences between classical phenotypes of multiple sclerosis. J Neurol Sci. 2015 Feb;349(1–2):10–4.
[6] Nourbakhsh B, Mowry EM. Multiple sclerosis risk factors and pathogenesis. Continuum (Minneap Minn). 2019 Jun;25(3):596–610.
[7] Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011 Oct;164(4):1079–106.
[8] Gran B, O’Brien K, Fitzgerald D, Rostami A. Experimental autoimmune encephalomyelitis. Handbook of neurochemistry and molecular neurobiology A. Lajtha. Heidelberg: Springer; 2007.
[9] Bert A, Gran B, Weissert R. EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med. 2011 Mar;17(3):119–25.
[10] Teixeira SA, Varrooni AA, Bolonhais SM, Muscará MN. Experimental autoimmune encephalomyelitis: a heterogeneous group of animal models to study human multiple sclerosis. Drug Discov Today Dis Models. 2005;2(2):127–34.
[11] Glatigny S, Bettelli E. Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS). Cold Spring Harb Perspect Med. 2018 Nov;8(11):a028977.
[12] Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol. 2002 Jul;169(1):117–25.
[13] Foster SC, Daniels C, Bourdette DN, Bebo BF Jr. Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol. 2003 Jul;140(1–2):78–87.
[14] Riskind PN, Massaccesi L, Doolittle TH, Hauser SL. The role of prolactin in autoimmun demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol. 1991 May;29(5):542–7.
[15] Dijkstra CD, van der Voort ER, De Groot CJ, Huitinga I, Uitdehaag BM, Polman CH, et al. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology. 1994;19(2):335–42.
[16] Canonicoh PL, Sortino MA, Favit A, Allepo G, Scapagnini U. Dihydroergocryptine protects from acute experimental allergic encephalomyelitis in the rat. Funct Neurol. 1993 May–Jun;8(3):183–8.
[17] Esquifino AI, Cano P, Zapata A, Cardinali DP. Experimental allergic encephalomyelitis in pituitary-grafted Lewis rats. J Neuroinflammation. 2006 Aug;3(1):20.
[18] Costanza M, Musio S, Abou-Hamdan M, Binart N, Pedotti R. Prolactin is not required for the development of severe chronic experimental autoimmune encephalomyelitis. J Immunol. 2013 Sep;191(5):2082–8.
[19] Zheng Nilsitsky S, Johnson TA, Metz LM, Weiss S, Yong VW. Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis. J Neuroinflammation. 2015 Mar;12(1):55.
[20] Zhang C, Ravenby NJ, Hohjoh H, Tomi C, Oki S, Yamamura T. Extrapyramidal prolactin promotes generation of Eomes-positive helper T cells mediating neuroinflammation. Proc Natl Acad Sci USA. 2019 Oct;116(42):21311–9.
[21] Esquifino AI, Cano P, Jiménez V, Cutrera RA, Cardinali DP. Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction. J Physiol Biochem. 2004 Dec;60(4):245–52.
[22] Shohreh R, Pardo CA, Guaraldi F, Schally AV, Salvatori R, GH, but not GHRH, plays a role in the development of experimental autoimmune encephalomyelitis. Endocrinology. 2011 Oct;152(10):3803–10.
[23] Duckers HJ, van Dokkum RP, Verhaagen J, Lopes da Silva FH, Gispel WH. Functional and neurophysiological evidence of the efficacy of trophic pharmacotherapy using an adrenocorticotropic hormone4-9 analog in experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Neuroscience. 1996 Mar;71(2):507–21.
[24] Duckers HJ, van Dokkum RP, Verhaagen J, van Luijtelael EL, Coenen AM, Lopes da Silva FH, et al. Neurotrophic ACTH4-9 analogue therapy normalizes electroencephalographic alterations in chronic experimental allergic encephalomyelitis. Eur J Neurosci. 1998 Dec;10(12):3709–20.
[25] Weidenfeld J, Karussis D, Abramsky O, Lehmann D, Arbel I, Ovadia H. Lomidone activates the adrenocortical axis in the rat: inhibition of experimental autoimmune encephalomyelitis by lomidone is not related to the increase of corticosterone. J Neuroimmunol. 1997 Oct;79(1):49–53.
[26] Stefferl A, Linnington C, Holsooer F, Reul JM. Susceptibility and resistance to experimental allergic encephalomyelitis: relationship with hypothalamic-pituitary-adrenocortical axis responsiveness in the rat. Endocrinology. 1999 Nov;140(1):4932–8.
[27] Huitinga I, Schmidt ED, van der Cammen MJ, Binnekead R, Tilders FJ. Priming with interleukin-1beta suppresses experimental allergic encephalomyelitis in the Lewis rat. J Neuroendocrinol. 2000 Dec;12(12):1186–93.
[28] Quintanar-Stepano A, Chavira-Ramírez R, Kovacs K, Berzci I. Neurointermediate pituitary lobectomy decreases the incidence and severity of experimental autoimmune encephalomyelitis in Lewis rats. J Endocrinol. 2005 Jan;184(1):51–8.
[29] Quintanar-Stepano A, Organista-Esparza A, Chavira-Ramírez R, Kovacs K, Berzci I. Effects of neurointermediate pituitary lobectomy and desmopressin on acute experimental autoimmune encephalomyelitis in Lewis rats. Neuroimmunomodulation. 2012;19(3):148–57.
[30] Wei Z, Deng X, Hong M, Su Q, Liu A, Huang Y, et al. Icaritin has synergistic effects with methylprednisolone to ameliorate EAE via modulating HPA function, promoting anti-
inflammatory and anti-apoptotic effects. Int J Clin Exp Med. 2015 Nov;8(11):2018–8.

[31] Ruocco HH, Fernandes GA, Namer IJ, Depaulis A, Levy S. Hypothalamic response to experimental allergic encephalomyelitis: role of substance P. Neuroimmunomodulation. 2004;11(1):28–35.

[32] Miller H, Newell DJ, Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticosteroids (A.C.T.H.). Lancet. 1961 Nov;2(7212):1120–2.

[33] Cusick MF, Libbey JE, Oh L, Jordan S, Fujimani RS. Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis. Autoimmunity. 2015 Jun;48(4):222–30.

[34] Zhang J, Markovic-Plese S, Labet B, Raus J, Weiner HL, Hafer DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994 Mar;179(3):973–84.

[35] Brod SA, Hood ZM. Ingested (oral) ACTH inhibits EAE. J Neuroimmunol. 2011 Mar;232(1–2):131–5.

[36] Dittel BJ, Dittel BN, Brod SA. Ingested ACTH blocks Th17 production by inhibiting GALT IL-6. J Neurosci. 2020 Feb;40(9):116602.

[37] Víñuela-Berní V, Gómez-Gonzálvez B, Quintanar-Stephano A. Blockade of arginine vasopressin receptors prevents blood-brain barrier breakdown in experimental autoimmune encephalomyelitis. Sci Rep. 2020 Jan;10(1):467.

[38] Tanaka K, Saito R, Sanada K, Nishimura H, Nishimura K, Sonoda S, et al. Expression of hypothalamic feeding-related peptide genes and neuroendocrine responses in an experimental allergic encephalomyelitis rat model. Peptides. 2020 Jul;129:170313.

[39] White SR, Samathanam GK, Bowker RM, Wessendorf MW. Damage to bulbospinal serotonin-, tyrosine hydroxylase-, and TRH-containing axons occurs early in the development of experimental allergic encephalomyelitis in rats. J Neurosci Res. 1990 Sep;27(1):89–98.

[40] Brod SA, Bauer V. Ingested (oral) thyrotropin releasing factor (TRH) inhibits EAE. Cytokine. 2013 Jan;61(1):323–8.

[41] Quintanar JL, Salinas E, Quintanar-Stephano A. Gonadotropin-releasing hormone reduces the severity of experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Neuropeptides. 2011 Feb;45(1):43–8.

[42] Güzmán-Soto I, Salinas E, Hernández-Jasso I, Quintanar JL. Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis. Neurochem Res. 2012 Oct;37(10):2190–7.

[43] Güzmán-Soto I, Salinas E, Quintanar JL. Leuprolide acetate inhibits spinal cord inflammatory response in experimental autoimmune encephalomyelitis by suppressing NF-kB activation. Neuroimmunomodulation. 2016;23(1):33–40.

[44] Ikushima H, Kanaoka M, Kojima S. Cutting edge: requirement for growth hormone-releasing hormone in the development of experimental autoimmune encephalomyelitis. J Immunol. 2003 Sep;171(6):2769–72.

[45] Purba JS, Raadsheer FC, Hofman MA, Ravid R, Polman CH, Kamphorst W, et al. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology. 1995 Jul;62(1):62–70.

[46] Calzà L, Giardino L, Pozza M, Micera A, Aloe L. Time-course changes of nerve growth factor, corticotropin-releasing hormone, and nitric oxide synthase isoforms and their possible role in the development of inflammatory response in experimental allergic encephalomyelitis. Proc Natl Acad Sci USA. 1997 Apr;94(7):3368–73.

[47] Benou C, Wang Y, Imitola J, VanVlerken L, Chandras C, Karalis KP, et al. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2005 May;174(9):5407–13.

[48] Muhvić D, Radošević-Stasić B, Pugal E, Rukavina D, Sepeć J, Efendić S. Modulation of experimental allergic encephalomyelitis by somatostatin. Ann N Y Acad Sci. 1992 Apr 1;650:170–8.

[49] Muhvić D, Barac-Latas V, Rukavina D, Radošević-Stasić B. Induction of experimental allergic encephalomyelitis in a low-susceptible Albino Oxford rat strain by somatostatin analogue SMS 201.995. Neuroimmunomodulation. 2005;12(1):20–8.

[50] Brod SA, Hood ZM. Ingested (oral) SST inhibits EAE. Autoimmunity. 2011 Aug;44(5):437–43.

[51] Constantinescu CS, Hilliard B, Ventura E, Rostami A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology. 1997;65(4):190–4.

[52] Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, et al. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci. 2001 Aug;2(2):85–9.

[53] Álvarez-Sánchez N, Cruz-Chamorro I, López-González A, Utrilla JC, Fernández-Santos JM, Martínez-López A, et al. Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun. 2015 Nov;50:101–14.

[54] Chen SJ, Huang SH, Chen JW, Wang KC, Yang YR, Liu PF, et al. Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2016 Feb;31:169–77.

[55] Ghareghani M, Dokoohaki S, Ghanbari A, Farhari N, Zibara K, Khodadoust S, et al. Melatonin exacerbarates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: a potential biomarker of multiple sclerosis progression. Clin Exp Pharmacol Physiol. 2017 Jan;44(1):52–61.

[56] Ghareghani M, Zibara K, Sadeghi H, Farhari N. Spasticity treatment ameliorates the efficacy of melatonin therapy in experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Cell Mol Neurobiol. 2018 Jul;38(5):1145–51.

[57] Ghareghani M, Scavo L, Jand Y, Farhari N, Sadeghi H, Ghanbari A, et al. Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis. Front Pharmacol. 2019 Feb;10:147.

[58] Ortega-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nat Rev Endocrinol. 2014 Oct;10(10):582–91.
[59] Rogister B, Ben-Hur T, Dubois-Dalcq M. From neural stem cells to myelinating oligodendrocytes. Mol Cell Neurosci. 1999 Oct-Nov;14(4–5):287–300.

[60] Calza L, Fernandez M, Giuliani A, Aloe L, Giardino L. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci USA. 2002 Mar;99(5):3258–63.

[61] Farsettii A, Mitsuhashi T, Desvergne B, Robbins J, Nikodem VM. Molecular basis of thyroid hormone regulation of myelin basic protein gene expression in rodent brain. J Biol Chem. 1991 Dec;266(34):23226–32.

[62] Gallo V, Armstrong RC. Developmental and growth factor-induced regulation of nestin in oligodendrocyte lineage cells. J Neurosci. 1995 Jan;15(1 Pt 1):394–406.

[63] Lezoualc'h F, Seugnet I, Monnier AL, Ghysdael J, Behr JP, Demeneix BA. Inhibition of neurogenic precursor proliferation by antisense alpha thyroid hormone receptor oligonucleotides. J Biol Chem. 1995 May;270(20):12100–8.

[64] Albornoz EA, Carreño LJ, Cortés GM, Gonzalez PA, Cisternas PA, Cautivo KM, et al. Gestational hypothyroidism increases the severity of experimental autoimmune encephalomyelitis in adult offspring. Thyroid. 2013 Dec;23(12):1627–37.

[65] Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of Th helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med. 2000 May;191(10):1799–806.

[66] Diab A, Deng C, Smith JD, Hussain RZ, Panavanh B, Lovett-Racke AE, et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2002 Mar;168(5):2508–15.

[67] Racke MK, Gocke AR, Muir M, Diab A, Drew PD, Lovett-Racke AE. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr. 2006 Mar;136(3):700–3.

[68] Klotsz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, et al. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med. 2009 Sep;206(10):3159.

[69] Fernandez M, Giuliani A, Pirondi S, D'Intino G, Giardino L, Aloe M, et al. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA. 2004 Nov;101(46):16363–8.

[70] Calzà L, Fernandez M, Giuliani A, D’Intino G, Pirondi S, Sivilla S, et al. Thyroid hormone and remyelination in adult central nervous system: a lesson from an inflammatory-demyelinating disease. Brain Res Brain Res Rev. 2005 Apr;48(2):339–46.

[71] Boelen A, Mikita J, Boiziau C, Chassande O, Fliers E, Petry KG. Type 3 deiodinase expression in inflammatory spinal cord lesions in rat experimental autoimmune encephalomyelitis. Thyroid. 2009 Dec;19(12):1401–6.

[72] Guadaño-Fernáez A, Obregón MJ, St Germain DL, Bernal J. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci USA. 1997 Sep;94(19):10391–6.

[73] Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. FEBS Lett. 2008 Jan;582(1):2–9.

[74] Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab. 2007 Jun;21(2):193–208.

[75] Fernández M, Paradisi M, Del Vecchio G, Giardino L, Calza L. Thyroid hormone induces glial lineage of primary neurospheres derived from non-pathological and pathological rat brain: implications for remyelination-enhancing therapies. Int J Dev Neurosci. 2009 Dec;27(8):769–78.

[76] D’Intino G, Lorenzini L, Fernandez M, Tagliani A, Perretta G, Del Vecchio G, et al. Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism. J Neuroendocrinol. 2011 Sep;23(9):778–90.

[77] Dell’Acqua ML, Lorenzini L, D’Intino G, Sivilla S, Pasqualetti P, Panetta V, et al. Functional and molecular evidence of myelin- and neuroprotection by thyroid hormone administration in experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol. 2012 Aug;38(5):454–70.

[78] Castello-Branco G, Stridh P, Guerreiro-Cacas AO, Adzemovic MZ, Falcão AM, Marta M, et al. Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats. Neurobiol Dis. 2014 Nov;71:220–33.

[79] Kuwabara T, Ishikawa F, Yasuda T, Aritomi K, Nakano H, Tanaka Y, et al. CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells. J Immunol. 2009 Aug;183(4):2513–21.

[80] Li O, Liu JQ, Zhang H, Zheng P, Liu Y, Bai XF. CD62L is required for the priming of encephalitogenic T cells but does not play a major role in the effector phase of experimental autoimmune encephalomyelitis. Scand J Immunol. 2006 Aug;64(2):117–24.

[81] Haensgen H, Albornoz E, Opazo MC, Bugueño K, Jara Fernández EL, Binzberger R, et al. Gestational hypothyroxinaemia affects its offspring with a reduced suppressive capacity impairing the outcome of the experimental autoimmune encephalomyelitis. Front Immunol. 2018 Jun;9:1257.

[82] Becklund BR, Hansen DW Jr, Deluca HF. Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin. Proc Natl Acad Sci USA. 2009 Mar;106(12):4971–6.

[83] Becklund BR, James BJ, Gagel RF, Deluca HF. The calcitonin/calcitonin gene related peptide-α gene is not required for 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis. Arch Biochem Biophys. 2009 Aug;488(2):105–8.

[84] Tsuji F, Murai M, Oki K, Seki I, Ueda K, Inoue H, et al. Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents. Eur J Pharmacol. 2010 Feb;627(1–3):327–9.

[85] Matsuda R, Kezuka T, Nishiyama C, Usui Y, Matsuosawa Y, Okunuki Y, et al. Suppression of murine experimental autoimmune optic neuritis by mature dendritic cells transfected with calcitonin gene-related Peptide gene. Invest Ophthalmol Vis Sci. 2012 Aug;53(9):5475–85.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998 May;393(6683):333–9.

[86] Mikami N, Watanabe K, Hashimoto N, Miyagi Y, Suea K, Fukada S, et al. Calcitonin gene-related peptide enhances experimental autoimmune encephalomyelitis by promoting Th17-cell functions. Int Immunol. 2012 Nov;24(11):681–91.

Sardi C, Zambusi L, Finardi A, Ruffini F, Tolou AA, Dickerson IM, et al. Involvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Jun;271(1–2):18–29.

Meehan TF, Vanhoecke J, Prahl J, Deluca HF. Hypercalcaemia produced by parathyroid hormone suppresses experimental autoimmune encephalomyelitis in female but not male mice. Arch Biochem Biophys. 2005 Oct;442(2):214–21.

Ghareghani Majid, Scavo L, Arnoult D, Zibara K, Farhadi N. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Alldano P, Lucchese G, Trojano M. Treating multiple sclerosis in a model of experimental autoimmune encephalomyelitis by promoting Th17 cells. Proc Natl Acad Sci USA. 2000 Sep;97(19):10526–31.

[90] Marqués F, Mesquita SO, Sousa JC, Coppola G, Gao F, Geschwind DH, et al. Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci. 2012 Apr;6:33.

[91] Van Etten E, Branisteau DD, Overbergh L, Bouillon R, Ebrahimi FF, ffaldano P, Lucchese G, Trojano M. Treating multiple sclerosis in a model of experimental autoimmune encephalomyelitis by promoting Th17 cells. Proc Natl Acad Sci USA. 2000 Sep;97(19):10526–31.

[92] Nam Y, Kim JH, Seo M, Kim JH, Jin M, Jeon S, et al. Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues. J Biol Chem. 2014 Jun;289(24):16773–89.

[93] von Etten E, Branisteau DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C. Combination of a 1,25-dihydroxyvitamin D3 analog and bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone. 2003 Apr;32(4):397–404.

[94] Berard JL, Zarruk JG, Arbour N, Prat A, Yong VW, Jacques FH, et al. Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia. 2012 Jul;60(7):1145–59.

[95] Nam Y, Kim JH, Seo M, Kim JH, Jin M, Jeon S, et al. Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues. J Biol Chem. 2014 Jun;289(24):16773–89.

[96] Marques F, Mesquita SO, Sousa JC, Coppola G, Gao F, Geschwind DH, et al. Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci. 2012 Aug;6:33.

[97] Iaffaldano P, Luchese G, Trojano M. Treating multiple sclerosis with natalizumab. Expert Rev Neurother. 2011 Dec;11(12):1683–92.

[98] Ebrahimi-Kalani A, Soleimani Rad J, Kafami L, Mohamadnejad D, Habibi Roudkaren M, Khaki AA, et al. MS14 down-regulates lipocalin2 expression in spinal cord tissue in a model of multiple sclerosis in female C57BL/6. Iran Biomed J. 2020 Nov;24(6):409.

[99] Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000 Sep;97(19):10526–31.

[100] Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev. 2012 Jul;248(1):170–87.

[101] Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol. 2004 Dec;56(6):767–77.

[102] Zhang X, Li QY, Xiao BG. Anti-inflammatory effect of erythropoietin therapy on experimental autoimmune encephalomyelitis. Int J Neurosci. 2012 May;122(5):255–62.

[103] Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 2005 Feb;1034(1–2):34–9.

[104] Dasgupta S, Mazumder B, Ramani YR, Bhattacharyya SP, Das MK. Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis. Indian J Pharmacol. 2011 Sep;43(5):512–5.

[105] Savino C, Pedotti R, Baggì F, Ubiali F, Gallo B, Nava S, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol. 2006 Mar;172(1–2):27–37.

[106] Yuan R, Wang B, Lu W, Maeda Y, Dowling P. A distinct region in erythropoietin that induces immune/inflammatory modulation and tissue protection. Neurotherapeutics. 2015 Oct;12(4):850–61.

[107] Boz C, Ozmenoglu M, Veligolu S, Kilinc K, Orem A, Aliolgu Z, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg. 2006 Feb;108(2):124–8.

[108] Crocker SJ, Whitmire JK, Frazo RF, Cheruboomuang P, Soloway PD, Whitton JL, et al. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol. 2006 Dec;169(6):2104–16.

[109] Thorne M, Moore CS, Robertson GS. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol. 2009 Jun;211(1–2):92–100.

[110] Chen H, Luo B, Yang X, Xiong J, Liu Z, Jiang M, et al. Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms. Arch Biochem Biophys. 2005 Oct;442(4):170–7.

[111] Mengozzi M, Cervellini I, Bigini P, Martone S, Biondi A, Pedotti R, et al. Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis. Mol Med. 2008 Nov–Dec;14(11–12):682–8.

[112] Chen SJ, Wang YL, Lo WT, Wu CC, Hsieh CW, Huang CF, et al. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010 Nov;162(2):210–23.

[113] Moransard M, Bednar M, Frei K, Gassmann M, Ogunshola OO. Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms. J Neuroinflammation. 2017 Oct;14(1):202.

[114] Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, et al. Neuroprotective effects and intracelular signaling pathways of erythropoietin in a rat model of multiple
sclerosis. Cell Death Differ. 2004 Dec;11(S2 Suppl 2): S181–92.

[115] Diem R, Sättler MB, Merkler D, Demmer I, Maier K, Stadelmann C, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain. 2005 Feb;128(2 Pt 2):735–85.

[116] Gaind D, Choi YB, Marchese M, Dowling P, Cook S, Blumberg B, et al. Prolonged beneficial effect of brief erythropoietin peptide JM4 therapy on chronic relapsing EAE. Neurotherapeutics. 2020 Sep;1–11. doi: 10.1007/s13310-020-00923-5.

[117] Pytski VI, Siusiukin IP. Conversion of cortisone into cortisol in the liver of guinea pigs during allergic processes of immediate and delayed types. Prob Endokrinol (Mosk). 1972 May–Jun;18(3):96–100.

[118] Pytski VI, Siusiukin IP. Cortisol metabolic intensity in the liver of guinea pigs in allergic processes of the immediate and delayed types. Biull Eksp Biol Med. 1976 Aug;82(8):981–4.

[119] Pytski VI, Arutjunova EE. Kinetics and properties of a cortisol-resistant population of lymphocytes from the lymph nodes of guinea pigs with experimental allergic encephalomyelitis. Biull Eksp Biol Med. 1977 Feb;83(2):200–2.

[120] Herrada AA, Contreras FJ, Marini NP, Amador CA, Gonzalez PA, Cortes CM, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010 Jan;184(1):191–202.

[121] Wesselmann U, Konkol RJ, Leo GL, Roerig DL, Harder DR. Altered splenic catecholamine concentrations during experimental allergic encephalomyelitis. Pharmacol Biochem Behav. 1987 Apr;26(4):851–4.

[122] Dowell KC, Gienapp IE, Stuckman S, Wardrop RM, Whitacre CC. Neuroendocrine modulation of chronic relapsing experimental autoimmune encephalomyelitis: a critical role for the hypothalamic-pituitary-adrenal axis. J Neuroimmunol. 1999 Dec;100(1–2):243–51.

[123] Yang P, Tian H, Zou YR, Chambon P, Ichinose H, Honig G, et al. Epinephrine production in Th17 cells and experimental autoimmune encephalitis. Front Immunol. 2021 Feb;12:616583.

[124] White SR, Bhatnagar RK, Bardo MT. Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J Neurochem. 1983 Jun;40(6):1771–3.

[125] Krenger W, Honegger CG, Feurer C, Cammisuli S. Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord. J Neurochem. 1986 Oct;47(4):1247–54.

[126] Abramsky O, Wertman E, Reches A, Brenner T, Ovadia H. Effect of hypothalamic lesions on experimental autoimmune diseases in rats. Ann N Y Acad Sci. 1987;496(1):360–5.

[127] Karpus WJ, Konkol RJ, Killen JA. Central catecholamine neurotoxin administration. 1. Immunological changes associated with the suppression of experimental autoimmune encephalomyelitis. J Neuroimmunol. 1988 Apr;18(1):61–73.

[128] Konkol RJ, Wesselmann U, Karpus WJ, Leo GL, Killen JA, Roerig DL. Suppression of clinical weakness in experimental autoimmune encephalomyelitis associated with weight changes, and post-decapitation convulsions after intracisternal-ventricular administration of 6-hydroxydopamine. J Neuroimmunol. 1990 Jan;26(1):25–34.

[129] Simonini MV, Polak PE, Sharp A, McGuire S, Galea E, Feinstein DL. Increasing CNS noradrenaline reduces EAE severity. J Neuroimmun Pharmacol. 2010 Jun;5(2):252–9.

[130] Polak PE, Kalinin S, Feinstein DL. Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain. 2011 Mar;134(3 Pt 3):665–77.

[131] Polak PE, Kalinin S, Braun D, Sharp A, Lin SX, Feinstein DL. The vincamine derivative vindeburanol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus. J Neurochem. 2012 Apr;121(2):206–16.

[132] Leonard JP, MacKenzie FJ, Patel HA, Cuzner ML. Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis. Brain Behav Immun. 1991 Dec;5(4):328–38.

[133] Balkowiec-Iskra E, Kurkowska-Jastrzębska I, Joniec I, Ciesielska A, Czlonkowska A, Czlonkowska A. Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration. Acta Neurobiol Exp (Wars). 2007;67(4):379–88.

[134] Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G, et al. Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nat Immunol. 2015 Dec;16(12):1228–34.

[135] Vujnović I, Plipović I, Jasić N, Petrović R, Blagojević V, Arsenović-Ranin N, et al. Noradrenaline through β-adrenoceptor contributes to sexual dimorphism in primary CD4⁺ T-cell response in DA rat EAE model? Cell Immunol. 2019 Feb;336:48–57.

[136] Plipović I, Vujnović I, Stojić-Vukanić Z, Petrović R, Kosec D, Nakća-Aleksić M, et al. Noradrenaline modulates CD4⁺ T cell priming in rat experimental autoimmune encephalomyelitis: a role for the α1-adrenoceptor. Immunol Res. 2019 Jun;67(2–3):223–40.

[137] Shipaeva EV, Kovalenko LP, Sorokina AV, Kovalov GI, Tallerova AV, Kolik LG, et al. Study of anti-inflammatory effects of GB-115, a glycine-containing retropedptide cholecystokinin analog. Bull Exp Biol Med. 2011 Mar;150(5):599–602.

[138] Bedou S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, et al. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol. 2003 Oct;171(7):3451–8.

[139] Dimitrijević M, Mitić K, Kuštrimović N, Vujič V, Stanojević S. NPY suppressed development of experimental autoimmune encephalomyelitis in Dark Agouti rats by disrupting costimulatory molecule interactions. J Neuroimmunol. 2012 Apr;245(1–2):23–31.

[140] Brod SA, Bauer VL. Ingested (oral) neuropeptide Y inhibits EAE. J Neuroimmunol. 2012 Sep;250(1–2):44–9.

[141] Theil MM, Miyake S, Mizuno M, Tomi C, Croxford JL, Hosoda H, et al. Suppression of experimental autoimmune encephalomyelitis by ghrelin. J Immunol. 2009 Aug;183(4):2859–66.
Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, et al. Fluoxetine suppresses development of axonal damage in rats inoculated for experimental allergic encephalomyelitis. J Neuroimmunol. 2017 Dec;313:77–80.

Babington RG, Wedeking PW. The inactivation of neurogenic 5-hydroxytryptamine receptors in guinea pigs with experimental allergic encephalomyelitis (EAE) induced paralysis. Brain Res. 1977 Apr;125:269–81.

Simmons RD, Buzbee TM, Linthicum DS. Methysergide, a serotonin antagonist, does not inhibit the expression of autoimmunity encephalomyelitis in the rabbit. J Neuroimmunol. 1989 Mar;142:1476–81.

Freire-Irgas M, Núñez MJ, Balsalobre J, García-Vallejo LA, Argibay S, Rodrigo E, et al. Administration of the 5-hydroxytryptamine (1A) receptor antagonist WAY100635 suppresses acute experimental allergic encephalomyelitis in Lewis rats. Neurosci Lett. 2003 May;342(1–2):33–6.

Simons RD, Buzbee TM, Linthicum DS. Methysergide, a serotonin antagonist, does not inhibit the expression of autoimmunity encephalomyelitis in the rabbit. J Neuroimmunol. 1989 Mar;42(1):77–9.

Samathanam GK, White SR, Kalivas PW, Duffy P. Effects of 5-hydroxytryptophan on extracellular serotonin in the spinal cord of rats with experimental allergic encephalomyelitis. Brain Res. 1991 Sep;559(1):37–43.

White SR, Black PC, Samathanam GK, Paros KC. Prazosin suppresses development of axonal damage in rats inoculated for experimental allergic encephalomyelitis. J Neuroimmunol. 1992 Aug;39(3):211–8.

Taler M, Gil-Ad I, Korob I, Weissman A. The immunomodulatory effect of the antidepressor sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2011;18(2):117–22.

Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, et al. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation. 2012;19(4):201–8.

Bhat R, Mahapatra S, Axtell RC, Steinman L. Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. J Neuroimmunol. 2017 Dec;313:77–81.

Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, et al. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017 Jul;7(1):4923.
Cannella B, Pitt D, Capello E, Raine CS. Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am J Pathol. 2000 Sep;157(3):933–43.

Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBIO Mol Med. 2014 Nov;6(11):1423–35.

Genoud S, Maricic I, Kumar V, Gage FH. Targeted expression of IGF-1 in the central nervous system fails to protect mice from experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005 Nov;168(1–2):40–5.

DiToro D, Harbour SN, Bando JK, Benavides G, Witte S, Laufer VA, et al. Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity. J Neuroimaging. 2020 Apr;52(4):650–67.

Verda L, Luo K, Kim DA, Bronesky D, Kohm AP, Miller SD, et al. Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitis. Bone Marrow Transplant. 2006 Sep;38(6):453–60.

Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan;19(1):3–8.

Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, Liblau RS, et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol. 2014 Aug;128(2):247–66.

Zarruk JG, Berard JL, Passos dos Santos R, Kroner A, Lee J, Arosio P, et al. Expression of iron homeostasis proteins in the spinal cord in experimental autoimmune encephalomyelitis and their implications for iron accumulation. Neurobiol Dis. 2015 Sep;81:93–107.

Čurko-Cofek B, Grubič Kezele T, Barac-Latas V, Hepcidin and metallothioneins as molecular base for sex-dependent differences in clinical course of experimental autoimmune encephalomyelitis in chronic iron overload. Med Hypotheses. 2017 Sep;107:51–4.

Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK, Di Tuoro A, et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol. 2001 May;166(10):5909–16.

Matarese G, Sanna V, Di Giacomo A, Lord GM, Howard JK, Bloom SR, et al. Leptin potentiates experimental autoimmune encephalomyelitis in SJL female mice and confers susceptibility to males. Eur J Immunol. 2001 May;31(5):1324–32.

De Rosa V, Proccacini C, La Cava A, Chieffi P, Nicoletti GF, Fontana S, et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest. 2006 Feb;116(2):447–55.

Takahashi K, Suwa H, Ishikawa T, Kotani H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest. 2002 Dec;110(12):1791–9.

Musio S, Gallo B, Scabeni S, Lapilla M, Poliani PL, Matarese G, et al. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. J Immunol. 2006 Jan;176(1):17–26.

Wu X, Hschouh H, Kastin AJ, Mishra PK, Pan W. Upregulation of astrocytic leptin receptor in mice with experimental autoimmune encephalomyelitis. J Mol Neurosci. 2013;49(3):446–56.

Mishra PK, Hschouh H, Ouyang S, Kastin AJ, Wu X, Pan W. Loss of astrocytic leptin signaling worsens experimental autoimmune encephalomyelitis. Brain Behav Immun. 2013 Nov;34:98–107.

Ouyang S, Hschouh H, Kastin AJ, Mishra PK, Wang Y, Pan W. Leukocyte infiltration into spinal cord of EAE mice is attenuated by removal of endothelial leptin signaling. Brain Behav Immun. 2014 Aug;40:61–73.

Piccio L, Stark JL, Cross AH. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol. 2008 Oct;84(4):940–8.

Gerriets VA, Danzaki K, Kishton RJ, Eisner W, Nichols AG, Saucillo DC, et al. Leptin directly promotes T cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. Eur J Immunol. 2016 Aug;46(8):1970–83.

Piccio L, Cantoni C, Henderson JG, Hawiger D, Ramsbottom M, Mikesell R, et al. Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. Eur J Immunol. 2013 Aug;43(8):2089–100.

Zhang K, Guo Y, Ge Z, Zhang Z, Da Y, Li W, et al. Adiponectin suppresses T helper 17 cell differentiation and limits autoimmune CNS inflammation via the SIRT1/PPARγ/RORγt pathway. Mol Neurobiol. 2017 Sep;54(7):4908–20.